

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner # : _____ Date: _____
 Art Uni: _____ Phone Number 30 _____ Serial Number: _____
 Mail Bx and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 CM1 1E07 - 703-308-4498
 jan.delaval@uspto.gov

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher:	<u>LM</u>	NA Sequence (#)	STN _____
Searcher Phone #:	<u>4198</u>	AA Sequence (#)	Dialog _____
Searcher Location:		Structure (#)	Questel/Orbit _____
Date Searcher Picked Up:	<u>2/21/02</u>	Bibliographic	Dr. Link _____
Date Completed:	<u>3/26/02</u>	Litigation	Lexis/Nexis _____
Searcher Prep & Review Time:	<u>3:00</u>	Fulltext	Sequence Systems <input checked="" type="checkbox"/>
Clerical Prep Time:	<u>45</u>	Patent Family	WWW/Internet _____
Online Time:		Other	Other (specify) _____

p58093fe

Welcome to DIALOG

Dialog level 02.01.23D

Last logoff: 26feb02 07:45:58

Logon file001 26feb02 13:26:37

File 1:ERIC 1966-2002/Feb 05

(c) format only 2002 The Dialog Corporation

Set Items Description

--- -----

Cost is in DialUnits

? b 410

26feb02 13:26:38 User208760 Session D2007.1

\$0.29 0.082 DialUnits File1

\$0.29 Estimated cost File1

\$0.29 Estimated cost this search

\$0.29 Estimated total session cost 0.082 DialUnits

File 410:Chronolog(R) 1981-2002/Jan

(c) 2002 The Dialog Corporation

Set Items Description

--- -----

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

26feb02 13:26:45 User208760 Session D2007.2

\$0.00 0.073 DialUnits File410

\$0.00 Estimated cost File410

\$0.01 TYMNET

\$0.01 Estimated cost this search

\$0.30 Estimated total session cost 0.155 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2002/Feb W3

(c) 2002 BIOSIS

File 73:EMBASE 1974-2002/Feb W3

(c) 2002 Elsevier Science B.V.

*File 73: For information about Explode feature please
see Help News73.

File 155:MEDLINE(R) 1966-2002/Feb W3

File 399:CA SEARCH(R) 1967-2002/UD=13608

(c) 2002 AMERICAN CHEMICAL SOCIETY

*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.

Set Items Description

--- -----

? s (hyaluron?)20n) (hiv or aids)

0 HYALURON?)20N) (HIV

0 AIDS)

S1 0 (HYALURON?)20N) (HIV OR AIDS)

? s (hyaluron?) (20n) (hiv or aids)

48131 HYALURON?
304447 HIV
216046 AIDS
S2 43 (HYALURON?) (20N) (HIV OR AIDS)
? rd s2

...completed examining records
S3 29 RD S2 (unique items)
? t s3/7/all

3/7/1 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12759112 BIOSIS NO.: 200000512735
Hyaluronic acid and CD44 aids in the differentiation between mesothelioma from adenocarcinoma in serous effusions.
AUTHOR: Afify A(a); Michael C(a); Stern R
AUTHOR ADDRESS: (a)University of Michigan Hospital, Ann Arbor, MI**USA
JOURNAL: Laboratory Investigation 80 (3):p40A March, 2000
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the United States and Canadian Academy of Pathology New Orleans, Louisiana, USA March 25-31, 2000
ISSN: 0023-6837
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

3/7/2 (Item 2 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11934864 BIOSIS NO.: 199900180973
Biodegradable guide channels comprised of esters of **hyaluronic acids** for use in tissue repair as surgical **aids**.
AUTHOR: Dorigatti F; Favaro G; Callegaro L; Romeo A
AUTHOR ADDRESS: Trento**Italy
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1220 (2):p1340 March 9, 1999
ISSN: 0098-1133
RECORD TYPE: Citation
LANGUAGE: English

3/7/3 (Item 3 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10937985 BIOSIS NO.: 199799559130
Interaction of HIV-1 tat protein with heparin: Role of the backbone structure, sulfation, and size.
AUTHOR: Rusnati Marco; Coltrini Daniela; Oreste Pasqua; Zoppetti Giorgio; Albini Adriana; Noonan Douglas; D'Adda Di Fagagna Fabrizio; Giacca Mauro; Presta Marco(a)
AUTHOR ADDRESS: (a)Gen. Pathol., Dep. Biomedical Sci. Biotechnol., via Valsabbina 19, 25123 Brescia**Italy
JOURNAL: Journal of Biological Chemistry 272 (17):p11313-11320 1997
ISSN: 0021-9258
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Human immunodeficiency virus type 1 (HIV-1) Tat protein is released from infected cells. Extracellular Tat enters the cell where it stimulates the transcriptional activity of HIV-long terminal repeat (LTR) and of endogenous genes. Heparin modulates the angiogenic (Albini, A., Benelli, R., Presta, M., Rusnati, M., Ziche, M., Rubartelli, A., Paglialunga, G., Bussolino, F., and Noonan, D. (1996) Oncogene 12,289-297) and transcriptional (Mann, D. A., and Frankel, A. D. (1991) EMBO J. 10, 1733-1739) activity of extracellular Tat. Here we demonstrate that heparin binds specifically to recombinant HIV-1 Tat produced as glutathione S-transferase (GST) fusion protein and immobilized on glutathione-agarose beads. Heparin and heparan sulfate (HS), but not dermatan sulfate, chondroitin sulfates A and C, **hyaluronic acid**, and K5 polysaccharide, competed with ³H-labeled heparin for binding to immobilized GST-Tat and inhibited **HIV**-LTR transactivation induced by extracellular GST-Tat. Selective 2-O-, 6-P-, total-O-desulfation, or N-desulfation/N-acetylation dramatically reduced the capacity of heparin to bind GST-Tat. Totally-O-desulfated and 2-Odesulfated heparins also showed a reduced capacity to inhibit the transactivating activity of GST-Tat. Very low molecular weight heparins showed a significant decrease in their capacity to bind GST-Tat and to inhibit its LTR transactivating activity when compared with conventional 13.6-kDa heparin. However, when 3.0-kDa heparin was affinity chromatographed on immobilized GST-Tat to isolate binding and non-binding subfractions, the Tat-bound fraction was about 1,000 times more potent than the unbound fraction in inhibiting the transactivating activity of GST-Tat. The results demonstrate that Tat interacts in a size-dependent manner with heparin/HS and that high affinity Tat-heparin interaction requires at least some 2-O-, 6-O-, and N-positions to be sulfated. The Tat binding activity of the glycosaminoglycans tested correlates with their capacity to affect the transactivating activity of extracellular Tat, indicating the possibility to design specific heparin/HS-like structures with Tat-antagonist activity.

3/7/4 (Item 4 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10179740 BIOSIS NO.: 199698634658
HIV acquires functional adhesion receptors from host cells.
AUTHOR: Guo Margaret M Lee; Hildreth James E K(a)
AUTHOR ADDRESS: (a)Leukocyte Immunoochemistry Lab., Dep. Pharmacology
Molecular Sciences, Johns Hopkins Univ. Sch. M**USA
JOURNAL: AIDS Research and Human Retroviruses 11 (9):p1007-1013 1995
ISSN: 0889-2229
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: CD4 is known to serve as the principal cellular receptor for HIV. However, several observations suggest that other molecules may be involved in infection of cells by HIV. Cell adhesion molecules and their ligands expressed on HIV-susceptible cells have been implicated in the biology of HIV in a number of studies. We have recently reported that HIV and SIV acquire cell adhesion molecules from host cells. We now report that a specific cell adhesion molecule, CD44, that is acquired by HIV retains its biological activity when expressed on the virus. We tested CEMx174 cells, which are CD4-positive and HIV-susceptible for phorbol ester-inducible binding to **hyaluronic acid** through CD44. Phorbol ester-stimulated but not unstimulated CEMx174 cells bound **hyaluronic acid**. Likewise, HIV from stimulated cells but not from unstimulated cells bound **hyaluronic acid** through acquired CD44 molecules. This is the first demonstration that adhesion molecules acquired by HIV are functional and the results imply that I-UV may

have the capacity to bind to any cell or substrate that its host cell binds to. The demonstration of functional adhesion receptors on HIV has important implications with respect to the tropism, infectivity, and dissemination of HIV.

3/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09906572 BIOSIS NO.: 199598361490
Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism.
AUTHOR: Dukes Carol S; Yu Yinhua; Rivadeneira Emilia D; Sauls Derrick L; Liao Hua-Xin; Haynes Barton F; Weinberg J Brice(a)
AUTHOR ADDRESS: (a)VA Med. Cent., 508 Fulton St., Durham, NC 27705**USA
JOURNAL: Journal of Virology 69 (7):p4000-4005 1995
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: CD4 is the predominant cell membrane protein that binds human immunodeficiency virus type 1 (HIV-1) gp120 and facilitates HIV-1 infection, but other membrane-associated molecules may be involved in determining HIV-1 cellular infection. Our prior work had suggested that CD44, the transmembrane receptor for **hyaluronan**, might play a role in the infection of mononuclear phagocytes with HIV-1. In the present work, we have used cells of the CD4-positive, CD44-negative human T-lymphoblast cell line Jurkat to study the role of CD44 in HIV-1 infection and tropism. Cells were transfected with cDNA for the standard (S, or hematopoietic) CD44 isoform CD44S or the epithelial isoform CD44E. The resultant lines expressed appropriate CD44S or CD44E mRNA and protein. While the parent Jurkat cells, those transfected with vector alone, and those transfected with CD44E could be productively infected with only the lymphocytotropic strain HIV-1-LAI, cells transfected with CD44S were rendered susceptible to productive infection with the monocytotropic strains HIV-1-BAL and HIV-1-ADA. Also, CD44S-transfected cells displayed higher levels of infection with HIV-1-LAI than did the other transfected Jurkat cells. The transfected cell line cells all had comparable growth rates and expressed similar levels of the membrane antigens CD4, CD7, major histocompatibility complex (MHC) class I, MHC class II, and CD11a, while levels of CD3 were slightly higher in cells transfected with vector alone and in one of the clones transfected with CD44S. Hyaluronan binding was increased in cells transfected with either CD44S or CD44E. Mouse NIH 3T3 fibroblasts transfected with human CD4, human CD44S, or both human CD4 and CD44S displayed the appropriate antigens, but they could not be productively infected with lymphocytotropic or monocytotropic strains of HIV-1. The results indicate that in human leukocytes, CD44S is an important determinant of HIV-1 productive infection and may be involved in viral cellular tropism.

3/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09842343 BIOSIS NO.: 199598297261
Acquisition of functional **hyaluronate** receptors by **HIV**.
AUTHOR: Guo Margaret M L; Hildreth James E K
AUTHOR ADDRESS: Dep. Pharmacol. Molecular Sci., Johns Hopkins Sch. Med., Baltimore, MD 21205**USA
JOURNAL: Journal of Cellular Biochemistry Supplement 0 (21B):p220 1995
CONFERENCE/MEETING: Keystone Symposium on HIV Pathogenesis Keystone,

Colorado, USA April 17-23, 1995

ISSN: 0733-1959

RECORD TYPE: Citation

LANGUAGE: English

3/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09688439 BIOSIS NO.: 199598143357

Hyaluronic acid through a new injectable nerve guide delivery system
enhances peripheral nerve regeneration in the rat.

AUTHOR: Seckel B R(a); Jones D; Hekimian K J; Wang K-K; Chakalis D P;
Gostas P D

AUTHOR ADDRESS: (a)Dep. Plastic Reconstructive Surgery, Lahey Clinic, 41
Mall Road, Burlington, MA 01805**USA

JOURNAL: Journal of Neuroscience Research 40 (3):p318-324 1995

ISSN: 0360-4012

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The use of non-neural conduits to bridge gaps in peripheral
nerves has been noted in the literature for many years. A logical
extension of this concept is the introduction of neurotrophic or growth
promoting factors into the lumen. We present here an injectable nerve
guide that allows percutaneous access to the microenvironment of the
regenerating peripheral nerve within the guide's lumen. Hyaluronic acid,
a compound associated with decreased scarring and improved fibrin matrix
formation, is added sequentially to the regenerating peripheral rat
sciatic nerve via this injectable nerve guide. Assessment of nerve
regeneration and reinnervation shows better conduction velocity, higher
axon counts, and a trend toward earlier myelination with **hyaluronic**
acid compared with saline. This work not only implies **hyaluronic**
acid's role as an agent that **aids** nerve growth but also describes a
new tool that allows percutaneous access to the milieu of a regenerating
nerve.

3/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09471101 BIOSIS NO.: 199497479471

Serum **hyaluronan** in **HIV** and in **AIDS** related Kaposi's
sarcoma.

BOOK TITLE: Tenth International Conference on AIDS and the International
Conference on STD, Vol 1; The global challenge of AIDS: Together for the
future

AUTHOR: Blum L(a); Guerchot J; Picard O; Cabane J; Giboudeau J; Imbert J C
BOOK AUTHOR/EDITOR: TENTH INTERNATIONAL CONFERENCE ON AIDS INTERNATIONAL
CONFERENCE ON STD

AUTHOR ADDRESS: (a)Hop. Saint Antoine, Paris**France
p1) 172 1994

BOOK PUBLISHER: Tenth International Conference on AIDS, Yokohama, Japan
CONFERENCE/MEETING: Meeting Yokohama, Japan August 7-12, 1994

RECORD TYPE: Citation

LANGUAGE: English

3/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08219819 BIOSIS NO.: 000043019667

HIV-1 INFECTION OF HUMAN MONOCYTES THE ROLE OF THE HYALURONATE RECEPTOR CD44

AUTHOR: RIVADENEIRA E D; MATTHEWS T J; HAYNES B F; WEINBERG J B
AUTHOR ADDRESS: V.A. MED. CENT., DURHAM, N.C. 27705.

JOURNAL: KEYSTONE SYMPOSIUM ON PREVENTION AND TREATMENT OF AIDS, KEYSTONE, COLORADO, USA, MARCH 27-APRIL 3, 1992. J CELL BIOCHEM SUPPL 0 (16 PART E). 1992. 100. 1992

CODEN: JCBSD

DOCUMENT TYPE: Meeting

RECORD TYPE: Citation

LANGUAGE: ENGLISH

3/7/10 (Item 10 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

08133888 BIOSIS NO.: 000093121036

BIOCHEMICAL AND MORPHOLOGICAL DIFFERENTIATION OF THE HUMAN COLONIC EPITHELIAL CELL LINE SW620 IN THE PRESENCE OF DIMETHYLSULFOXIDE

AUTHOR: OMARY M B; DE GRANDPRE L; MCCAFFREY M; KAGNOFF M F

AUTHOR ADDRESS: DEP. MED., STANFORD UNIV. SCH. MED., ROOM S-069, STANFORD, CALIF. 94305.

JOURNAL: J CELL BIOCHEM 48 (3). 1992. 316-323. 1992

FULL JOURNAL NAME: Journal of Cellular Biochemistry

CODEN: JCEBD

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: In vitro models of intestinal cell differentiation provide an important adjunct for studying normal and abnormal intestinal epithelial cell differentiation. The studies reported herein describe morphologic and biochemical changes in the colonic epithelial cell line SW620 following dimethylsulfoxide (DMSO) incubation. Cells cultured in the presence of DMSO showed striking changes in morphology characterized by enlargement, elongation, and formation of process-like structures by light microscopy and a propensity to form microvillus-like structures by electron microscopy. These changes were accompanied by significant differences in the expression of the cell surface markers CD4 (**HIV** gp120 receptor), CD44 (**hyaluronate** receptor), and KS1 (adenocarcinoma/epithelial specific antigen). There was a marked decrease in CD4 expression (38% to 2%), an increase in CD44 expression (4% to 50%) and a decrease in KS1 expression (98% to 66%) as detected by flow cytometry following incubation of SW260 cells in DMSO. Parallel changes in the expression of these markers were seen by metabolic and surface labeling studies. Although SW620 cells were infected by HIV-1, DMSO-treated SW620 cells could not be infected. DMSO-induced changes in surface expression of CD4, CD44, and KS-1 were reversible over time upon removal of DMSO from the culture medium. Secretory component, sucrase, neuron-specific enolase, chromogranin-A, and mucin were not detectable in SW620 cells with or without DMSO treatment. SW620 cells provide a useful model for studying specific biochemical and molecular events involved in intestinal epithelial cell differentiation and function.

3/7/11 (Item 11 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

07740888 BIOSIS NO.: 000041049684

POSSIBLE ROLE OF THE HYALURONATE RECEPTOR CD44 IN THE IN-VITRO INFECTON OF HUMAN MONOCYTES WITH HIV-1

AUTHOR: RIVADENEIRA E D; MATTHEWS T J; HAYNES B F; WEINBERG J B
AUTHOR ADDRESS: VA AND DUKE UNIV. MED. CENT., DURHAMS, N.C.
JOURNAL: JOINT MEETING OF THE ASSOCIATION OF AMERICAN PHYSICIANS, THE
AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, AND THE AMERICAN FEDERATION
FOR CLINICAL RESEARCH, SEATTLE, WASHINGTON, USA, MAY 3-6, 1991. CLIN RES 39
(2). 1991. 382A. 1991
CODEN: CLREA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

3/7/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

07252350 BIOSIS NO.: 000090032226
VITRAX SODIUM HYALURONATE IN ANTERIOR SEGMENT SURGERY A REVIEW AND CLINICAL
STUDY SUMMARY
AUTHOR: COBO M; BEATY N
AUTHOR ADDRESS: DUKE UNIV. EYE CENT., ERWIN RD., DURHAM, N.C. 27710.
JOURNAL: ADV THER 7 (2). 1990. 51-60. 1990
FULL JOURNAL NAME: Advances in Therapy
CODEN: ADTHE
DOCUMENT TYPE: Review
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Anterior segment ophthalmic surgery has been greatly facilitated by the use of viscoelastic surgical aids containing sodium hyaluronate. VITRAX is a highly purified fraction of sodium hyaluronate dissolved in a physiological balanced salt solution. A multiclinic evaluation was conducted in 440 patients undergoing anterior segment surgery who received VITRAX or other viscoelastic surgical aids (HEALON, VISCOAT, or AMVISC). VITRAX was effective in facilitating complex intraocular surgical procedures and was comparable to HEALON in protecting corneal endothelium during surgery. Overall rates for complications and adverse reactions with VITRAX and the comparative agents were similar, although postoperative elevations in intraocular pressure were observed more frequently with HEALON. VITRAX is an effective and well-tolerated surgical aid for anterior chamber procedures.

3/7/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

06889602 BIOSIS NO.: 000089043531
EVALUATIONS ON THE USEFULNESS OF VISCOUS AGENTS IN ANTERIOR SEGMENT SURGERY
II. EFFECT ON INTRAOCULAR PRESSURE AND CLEARANCE FROM THE ANTERIOR
CHAMBER
AUTHOR: MIYAUCHI S; IWATA S
AUTHOR ADDRESS: TOKYO RES. INST., SEIKAGAKU-KOGYO CO., LTD., 3-1253,
TATENO, HIGASHI-YAMATO, TOKYO 189, JPN.
JOURNAL: J OCUL PHARMACOL 5 (3). 1989. 221-232. 1989
FULL JOURNAL NAME: Journal of Ocular Pharmacology
CODEN: JOPHE
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Various viscous agents in anterior segment surgery were replaced with the aqueous humor of rabbit eyes. The effects of these agents on intraocular pressure (IOP) and their clearance from the anterior chamber

were studied. Furthermore, the degradation of these agents in ocular and hepatic tissues was investigated. The IOP after the injection of a 1% solution of sodium hyaluronate with a molecular weight of 790 .times. (Na-HA 103 (790 .times. 103, 1%)), fell to the normal level after 12 hours; however, after a 1 % solution of sodium hyaluronate with a molecular weight of 2160 .times. 103 (Na-HA) (2160 .times. 103, 1 %)), a 2% solution of methylcellulose with a molecular weight of 86 .times. 103 (MC (86 .times. 103, 2%)) or a 30% solution of sodium chondroitin sulfate with a molecular weight of 30 .times. 103 (Na-Chs (30 .times. 103, 30%)), the return of IOP to normal level required 24 hours. Six hours after the injection of MC (86 .times. 103, 2%), the IOP was significantly higher than those of other agents. Na-Chs (30 .times. 103, 30%) and Na-HA (790 .times. 103, 1%) were eliminated from the anterior chamber within 12 and 24 hours, respectively. Na-HA (2160 .times. 103, 1%) and MC (86 .times. 103, 2%) required 72 hours to be eliminated from the anterior chamber. The degradation of Na-HA was detected in extracts of the iris, corneo-scleral junction, and liver. The degradation of Na-Chs was also detected in the liver extract, but the degradation of MC was not detected. On the basis of these findings, and the results in our previous report with respect to the efficacy of the viscous agents, it is concluded that Na-HA is the best viscous agent to be used in anterior segment surgery.

3/7/14 (Item 1 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

11091444 EMBASE No: 2001110514
Cellular and noncellular components of bronchoalveolar lavage fluid in HIV-1-infected children with radiological evidence of interstitial lung damage
Midulla F.; Strappini P.; Sandstrom T.; Bjermer L.; Falasca C.; Capocaccia P.; Catania S.; Soldi E.; Villa M.P.; Ronchetti R.
Dr. F. Midulla, Cattedra di Clinica Pediatrica, Istituto di Clinica Pediatrica, Viale Regina Elena 324, 00161 Rome Italy
AUTHOR EMAIL: midulla@uniromal.it
Pediatric Pulmonology (PEDIATR. PULMONOL.) (United States) 2001, 31/3 (205-213)
CODEN: PEPUE ISSN: 8755-6863
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 40

Children with acquired immune deficiency syndrome (AIDS) commonly have recurrent infectious and noninfectious lung complications that ultimately end in death. To study the intensity of alveolar inflammation and to evaluate the clinical utility of bronchoalveolar lavage (BAL) in children with HIV-1 infections, we retrospectively analyzed differential cell counts, lymphocyte subsets, and fibronectin and hyaluronic acid concentrations in BAL fluid of 18 HIV-1-positive children (9 boys, mean age 3.5 years, range 5 months-8 years) with radiological evidence of interstitial lung disease, and 19 control children who had undergone BAL for clinical indications not involving the lung parenchyma (13 boys, mean age 3 years, range 2 months-14 years). BAL fluid from 89% of the HIV-1 infected children showed CD8 + ve lymphocytic alveolitis expressing HLA-DR, CD54, and CD 69 antigens. BAL fluid from HIV-infected patients typically contained markedly increased percentages and numbers of lymphocytes ($P < 0.0001$) and eosinophils ($P < 0.04$) and significantly higher concentrations of albumin ($P < 0.05$) and fibronectin ($P < 0.0006$) than fluids from control children. Whereas BAL cellular components did not differ in *P. carinii*-positive and *P. carinii*-negative HIV-1-infected children, fibronectin concentrations were significantly higher in *P. carinii*-positive than negative children. BAL cell differentials and noncellular components

were related neither to severity of disease nor to patients' disease progression. These findings indicate that BAL is useful in studying the intensity of lung inflammation in children with HIV-1 infections and radiologically documented interstitial lung disease, but provides no information on the subsequent clinical course. (c) 2001 Wiley-Liss, Inc.

3/7/15 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

07646546 EMBASE No: 1999138632
Fatal liver failure in haemophiliacs with HIV-induced immunodeficiency:
Observation of six patients
Toyoda H.; Fukuda Y.; Nakano I.; Katano Y.; Takamatsu J.; Saito H.;
Hayakawa T.
Dr. H. Toyoda, Second Department Internal Medicine, Nagoya University
School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8500 Japan
Haemophilia (HAEMOPHILIA) (United Kingdom) 1999, 5/2 (109-114)
CODEN: HAEMF ISSN: 1351-8216
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 21

We observed six cases of haemophiliacs with HIV-induced immunodeficiency who died from fatal liver failure despite the absence of evident cirrhosis. They all had the infection with hepatitis viruses (two patients with hepatitis B and D viruses and four patients with hepatitis C virus) and their CD4 counts were severely decreased. They were much younger than cirrhotic haemophiliacs without HIV. Their serum levels of **hyaluronic acid** and type IV collagen were lower than those in haemophiliacs with cirrhosis, and were normal. No patients had experienced symptoms or concomitant diseases characteristic of cirrhosis, such as ascites, jaundice, oesophageal/gastric varices or hepatocellular carcinoma, except for one case who had a history of mild ascites. The characteristics of this liver failure were different from liver failure resulting from cirrhosis caused by chronic hepatitis, which suggests liver failure that is specific to patients with immunodeficiency. This kind of liver failure can be a factor threatening survival in patients with HIV infection and with hepatitis virus co-infection in an immunodeficient state.

3/7/16 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

04299886 EMBASE No: 1990182442
VITAX (TM) (sodium hyaluronate) in anterior segment surgery: A review and
clinical study summary
Cobo M.; Beaty N.
Duke University Eye Center, Erwin Road, Durham, NC 27710 United States
Advances in Therapy (ADV. THER.) (United States) 1990, 7/2 (51-60)
CODEN: ADTHE ISSN: 0741-238X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Anterior segment ophthalmic surgery has been greatly facilitated by the use of viscoelastic surgical aids containing sodium **hyaluronate**. VITRAX (TM) is a highly purified fraction of sodium **hyaluronate** dissolved in a physiological balanced salt solution. A multiclinic evaluation was conducted in 440 patients undergoing anterior segment surgery who received VITRAX or other viscoelastic surgical aids (HEALON(R), VISCOAT(R), or AMVIS(R)). VITRAX was effective in facilitating complex intraocular surgical procedures and was comparable to HEALON in protecting

corneal endothelium during surgery. Overall rates for complications and adverse reactions with VITRAX and the comparative agents were similar, although postoperative elevations in intraocular pressure were observed more frequently with HEALON. VITRAX is an effective and well-tolerated surgical aid for anterior chamber procedures.

3/7/17 (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

11635929 21397516 PMID: 11505710

Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy.

Ritt MJ; Hillebrand-Haverkort ME; ten Veen JH
Department of Plastic, Reconstructive and Hand Surgery, Academic Medical Center, Amsterdam, The Netherlands. ritt@wxs.nl

Acta chirurgiae plasticae (Czech Republic) 2001, 43 (2) p54-6,
ISSN 0001-5423 Journal Code: OJO

Languages: ENGLISH

Document type: Clinical Trial; Journal Article

Record type: Completed

Localized facial lipodystrophy is a socially disabling complication affecting many HIV-seropositive patients receiving triple combination therapy. The exact pathogenesis is not well understood and proper therapy is not available. The purpose of this pilot-study was to determine whether a hyaluronic acid gel, used to treat wrinkles for cosmetic reasons, would be a safe and effective treatment for facial lipodystrophy in patients receiving triple combination therapy. Seven patients were treated with intradermal gel injections after skin tests. There were no immediate or late allergenic reactions or other side effects. Within the limitations of the product, overall satisfaction regarding the results was high.

Record Date Created: 20010816

3/7/18 (Item 2 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

09727605 98196580 PMID: 9537290

Characterization of cysteamine as a potential contraceptive anti-HIV agent.

Anderson RA; Feathergill K; Kirkpatrick R; Zaneveld LJ; Coleman KT; Spear PG; Cooper MD; Waller DP; Thoene JG

Rush Presbyterian-St. Luke's Medical Center, Ob/Gyn Research, Chicago, Illinois 60612-3864, USA.

Journal of andrology (UNITED STATES) Jan-Feb 1998, 19 (1) p37-49,
ISSN 0196-3635 Journal Code: HB4

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Cysteamine (beta-mercaptoproethylamine, or MEA) is a thiol-reducing agent and has anti-HIV activity. Because of these properties, cysteamine was evaluated as a vaginal contraceptive and tested for its effects on sperm function and on other sexually transmitted microbes. Cysteamine was contraceptive in the rabbit. Conception was inhibited completely when sperm were pretreated with 500 microg/ml cysteamine and was inhibited by more than 60% when 7.5 mg cysteamine was applied vaginally as a suspension in 50% K-Y Jelly. Cysteamine had multiple effects on spermatozoa. Both acrosin (EC 3.4.21.10) and hyaluronidase (EC 3.2.1.35) were reversibly inhibited by cysteamine. Calculated IC50 values were 370 microg/ml and 150 microg/ml for acrosin and hyaluronidase, respectively. Cysteamine behaved as a poor spermicide when activity was measured by the 30-second Sander-Cramer test. However, sperm motility was inhibited completely when cysteamine was preincubated for 10 minutes prior to motility evaluation, at concentrations as low as 50 microg/ml. The calcium ionophore A23187-induced human acrosome

reaction was inhibited by cysteamine (IC50 = 0.5 microg/ml). Neither herpes simplex virus nor *Neisseria gonorrhoeae* was affected by cysteamine at concentrations as high as 500 microg/ml and 100 microg/ml, respectively. Cysteamine appears to have no effect on normal vaginal flora (i.e., *lactobacillus*). These results, together with published data, strongly support the further development of cysteamine as a topical contraceptive anti-HIV agent.

Record Date Created: 19980513

3/7/19 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09365866 97341088 PMID: 9197562
Effects of viscoelastics on bovine corneal endothelial cells in vitro.
Zhu SN; Nolle B; Duncker G
University Eye Hospital, Kiel, Germany.
Acta ophthalmologica Scandinavica (DENMARK) Apr 1997, 75 (2) p155-8,
ISSN 1395-3907 Journal Code: CC4

Languages: ENGLISH
Document type: Journal Article
Record type: Completed
PURPOSE: To evaluate the possible toxic effects of sodium hyaluronate and hydroxypropyl methylcellulose on corneal endothelium. METHODS: Cultured bovine corneal endothelial cells (BCEC) were treated with either original Healon (10 mg/ml) or Methocel (20 mg/ml) for 1 h, or with various dilutions of these substances in culture medium for up to one week. The toxicity of the viscoelastics was assessed in terms of lactate dehydrogenase (LDH) release into the supernatant and of cell density. RESULTS: Neither Healon nor Methocel in a dilution of 2 mg/ml enhanced LDH release after 72 h incubation, when compared with the control in a confluent model. In a proliferation model neither diluted Healon nor Methocel showed apparent inhibitory or stimulatory effects on the growth of BCEC up to the highest concentration we tested. When a BCEC monolayer was covered for 1 h with either undiluted Healon or undiluted Methocel, a significant, though transient, higher LDH release was induced. CONCLUSION: The results indicate that the diluted viscoelastics are safe for long time contact with BCEC, but undiluted they may temporarily interfere with the metabolism of the cytoplasm membranes of BCEC.

Record Date Created: 19970729

3/7/20 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

02167845 69260743 PMID: 5801748
[Note on local treatment of mucoid cysts of the fingers]
Note sur un traitement local des kystes mucoides des doigts.
Labouche F; Lanchec C
Bulletin de la Societe francaise de dermatologie et de syphiligraphie (FRANCE) 1969, 76 (1) p90-2, Journal Code: COG
Languages: FRENCH
Document type: Journal Article
Record type: Completed
Record Date Created: 19690930

3/7/21 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

132275971 CA: 132(21)275971g PATENT
Cloning, sequence and recombinant production of phospholipase A1 and hyaluronidase of *Polistes annularis* venom, and their use in immunological

therapies

INVENTOR(AUTHOR) : King, Te Paio

LOCATION: USA

ASSIGNEE: The Rockefeller University

PATENT: PCT International ; WO 200018896 A1 DATE: 20000406

APPLICATION: WO 99US23211 (19991001) *US 166205 (19981001)

PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-009/18A; C12N-009/26B; C12N-015/10B; C12N-015/54B; A61K-039/35B

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA207005 Enzymes

CA203XXX Biochemical Genetics

CA204XXX Toxicology

CA212XXX Nonmammalian Biochemistry

CA215XXX Immunoochemistry

IDENTIFIERS: Polistes venom phospholipase A1 hyaluronidase intron cDNA sequence, antiallergic immunomodulator Polistes venom phospholipase A1 hyaluronidase

DESCRIPTORS:

Hymenoptera...

allergy to Hymenoptera venom; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Allergens... Allergy inhibitors... Antiviral agents... Anti-AIDS agents... cDNA sequences... Immunomodulators... Molecular cloning... Nucleic acid hybridization... Polistes annularis... Polistes... Protein sequences...

Venoms...

cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Immunity...

disorder, treatment of; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Enzymes, biological studies...

fusion products, phospholipase A1 with polyhistidine; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Allergy...

hypersensitivity, to Hymenoptera venom; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Human herpesvirus... Papillomavirus...

infection, treatment of; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Genetic element...

intron; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Drug delivery systems...

nasal; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Enzymes, biological studies...

of paper wasp venom; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Drug delivery systems...

oral; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies
Bacteria(Eubacteria)... Yeast...

paper wasp venom enzymes expression in; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Drug delivery systems...

pulmonary; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Drug delivery systems...

systemic; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Drug delivery systems...

topical; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

Autoimmune disease...

treatment of; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

CAS REGISTRY NUMBERS:

263496-42-0P 263496-60-2P amino acid sequence; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

9001-54-1P 9043-29-2P cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

9043-29-2DP fusion protein with polyhistidine sequence, cloning, sequence, and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

237729-45-2 263496-40-8 263496-41-9 263496-58-8 263496-59-9 nucleotide sequence; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

9013-93-8P of paper wasp venom; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of paper wasp venom, and their use in immunol. therapies

149120-03-6 159447-47-9 159447-48-0 263541-22-6 263541-23-7

263541-24-8 unclaimed protein sequence; cloning, sequence and recombinant prodn. of phospholipase A1 and hyaluronidase of Polistes annularis venom, and their use in immunol. therapies

3/7/22 (Item 2 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131000722 CA: 131(1)722k PATENT

Methods for cell mobilization using in vivo treatment with hyaluronan, and therapeutic methods

INVENTOR(AUTHOR): Pilarski, Linda May

LOCATION: Can.,

ASSIGNEE: Hyal Pharmaceutical Corporation

PATENT: Canada Pat Appl ; CA 2199756 AA DATE: 19980912

APPLICATION: CA 2199756 (19970312)

PAGES: 60 pp. CODEN: CPXXEB LANGUAGE: English CLASS: A61K-031/725A

SECTION:

CA201012 Pharmacology

CA263XXX Pharmaceuticals

IDENTIFIERS: hyaluronic acid cell mobilization therapeutic, hyaluronan cell mobilization therapeutic, hematopoietic cell mobilization hyaluronan, cancer treatment hematopoietic cell mobilization hyaluronan, organ

transplant hematopoietic cell mobilization hyaluronan

DESCRIPTORS:

Neoplasm...

cell, release from bone marrow and other tissue into blood; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Cytotoxic agents...

cytoreductive therapy before hematopoietic cell transplant; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Immunity...

disorder, immune reactivity-damaging conditions; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Allergy inhibitors... Antiasthmatics... Antitumor agents... Autoimmune disease... B cell(lymphocyte)... Bone marrow... Dendritic cell... Drug delivery systems... Erythroblast... Erythrocyte... Hematopoiesis...

Hematopoietic precursor cell... Monocyte... Polymorphonuclear leukocyte... T cell(lymphocyte)... Transplant and Transplantation... Transplant rejection...

hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Immunosuppressants...

immunosuppressive regimen optimization; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Hematopoietic precursor cell...

mast cell; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Lymphocyte...

plasma cell; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Cell...

stem; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Bone marrow...

stroma, stromal cell; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

Immunosuppression...

treatment of chemotherapy-induced; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

AIDS(disease)... Chemotherapy...

treatment of immunosuppression from; hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

CAS REGISTRY NUMBERS:

9004-61-9 9067-32-7 11096-26-7 83869-56-1 143011-72-7 hyaluronic acid for hematopoietic cell mobilization, and therapeutic methods

3/7/23 (Item 3 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

130029256 CA: 130(3)29256b PATENT

Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation

INVENTOR(AUTHOR): Falk, Rudolf E.; Asculai, Samuel S.

LOCATION: Can.,

ASSIGNEE: Hyal Pharmaceutical Corp.

PATENT: PCT International ; WO 9852613 A2 DATE: 19981126

APPLICATION: WO 98CA449 (19980511) *CA 2205692 (19970516)

PAGES: 104 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-047/36A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;

LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG
SECTION:

CA263006 Pharmaceuticals

CA201XXX Pharmacology

IDENTIFIERS: drug delivery hyaluronate electrotransport electroporation, penetration enhancement drug delivery hyaluronate electrotransport electroporation

DESCRIPTORS:

Steroids, biological studies...

antiinflammatory; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Detoxification (metabolic)...

detoxifying agents; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Transport (biological)...

electrotransport; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Antitumor agents...

gallbladder tumor inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Mesothelioma...

inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Squamous cell carcinoma inhibitors...

larynx tumor inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Antitumor agents...

mesothelioma inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Hair growth stimulants...

minoxidil; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Larynx...

squamous cell carcinoma inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Anti-inflammatory drugs...

steroidal; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Analgesics... Antibacterial agents... Antibiotics... Antitumor agents...

Antiviral agents... Anti-AIDS drugs... Anti-ischemic agents...

Bronchodilators... Chemotherapy... Cytotoxic agents... Diuretics... DNA...

Drug transport... Electroporation... Fungicides... Gene therapy... Hepatoma

inhibitors... Immunosuppressants... Interferon .alpha.... Interferon .beta.

... Lymphokines... Monoclonal antibodies... Nonsteroidal anti-inflammatory

drugs... Nucleic acids... Radical scavengers... Sarcoma inhibitors...

Transplant rejection... Transplant (organ)...

therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Bladder carcinoma inhibitors...

transitional cell carcinoma inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

Gallbladder...

tumor inhibitors; therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

CAS REGISTRY NUMBERS:

50-81-7 biological studies, therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

9004-61-9D derivs., therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

50-76-0 51-21-8 53-86-1 54-31-9 59-05-2 60-81-1 60-82-2 69-53-4

443-48-1 865-21-4 1403-66-3 1404-00-8 1492-18-8 9004-61-9

22204-53-1 25316-40-9 38304-91-5 41575-94-4 59865-13-3 74103-07-4

therapeutic agent administration using suitable forms of hyaluronic acid and combinations with electroporation

3/7/24 (Item 4 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

130000516 CA: 130(1)516a PATENT
Auxiliary agents for eye surgeries
INVENTOR(AUTHOR): Saito, Fumio; Tajiri, Taiji; Ishikawa, Eri; Takahashi, Yasuyuki
LOCATION: Japan,
ASSIGNEE: Offtecs K. K.
PATENT: Japan Kokai Tokkyo Koho ; JP 98290830 A2 ; JP 10290830 DATE:
19981104
APPLICATION: JP 97101708 (19970418)
PAGES: 6 pp. CODEN: JKXXAF LANGUAGE: Japanese CLASS: A61L-027/00A
SECTION:
CA201012 Pharmacology
IDENTIFIERS: eye surgery aid hyaluronate polyol
DESCRIPTORS:
Vinyl polymers...
carboxy-contg.; eye surgery aids contg. hyaluronates and viscosity
stabilizers
Amino acids, biological studies... Carbohydrates, biological studies... Eye
... Polyhydric alcohols... Polyoxyalkylenes, biological studies... Surgery
...
eye surgery aids contg. hyaluronates and viscosity stabilizers
Carboxylic acids, biological studies...
polycarboxylic; eye surgery aids contg. hyaluronates and viscosity
stabilizers
CAS REGISTRY NUMBERS:
50-70-4 56-81-5 57-50-1 57-55-6 71-00-1 74-79-3 107-21-1 biological
studies, eye surgery aids contg. hyaluronates and viscosity stabilizers
68-04-2 99-20-7 7585-39-9 9002-89-5 9004-32-4 9004-61-9 9067-32-7
17090-93-6 25322-68-3 eye surgery aids contg. hyaluronates and
viscosity stabilizers

3/7/25 (Item 5 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

125084393 CA: 125(7)84393r DISSERTATION
The role of CD44 in HIV infection (monocytes, adhesion, immune
deficiency, hyaluronic acid)
AUTHOR(S): Guo, Margaret Ming-Ti
LOCATION: Johns Hopkins Univ., Baltimore, MD, USA
DATE: 1996 PAGES: 198 pp. CODEN: DABBBA LANGUAGE: English CITATION:
Diss. Abstr. Int., B 1996, 57(1), 225 AVAIL: Univ. Microfilms Int., Order
No. DA9617526
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: CD44 antigen HIV monocyte adhesion
DESCRIPTORS:
Adhesion, bio-... Antigens, CD44... Monocyte, disease, infection...
Virus, animal, human immunodeficiency 1...
role of CD44 in HIV-1 infection of monocytes

3/7/26 (Item 6 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

122064475 CA: 122(6)64475d PATENT
Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
INVENTOR(AUTHOR): Kuo, Jin-Wen; Swann, David A.; Prestwich, Glenn D.
LOCATION: USA
ASSIGNEE: Research Foundation of State University of N.Y.; Anika Research, Inc.
PATENT: United States ; US 5356883 A DATE: 941018
APPLICATION: US 920698 (920728) *US 388578 (890801) *US 809399 (911218)
PAGES: 13 pp. Cont.-in-part of U.S. Ser. No.809,399, abandoned CODEN:
USXXAM LANGUAGE: English CLASS: 514054000; A61K-031/725A; A61K-031/735B;
A61K-047/26B; C08L-001/00B
SECTION:
CA263007 Pharmaceuticals
IDENTIFIERS: hyaluronate carbodiimide gel surgical aid, drug delivery vehicle hyaluronate gel
DESCRIPTORS:
Adhesion,bio-...
post-operative; water-insol. derivs. of hyaluronic acid for preventing postoperative adhesion between healing tissue
Pharmaceutical dosage forms...
prepn. of water-insol. derivs. of hyaluronic acid for use as surgical aids and drug delivery vehicles
Medical goods...
water-insol. derivs. of hyaluronic acid for preventing postoperative adhesion between healing tissue
CAS REGISTRY NUMBERS:
9004-61-9DP 9067-32-7DP reaction products with carbodiimides, prepn. of water-insol. derivs. of hyaluronic acid for use as surgical aids and drug delivery vehicles
1892-57-5DP 22572-40-3DP 134736-11-1DP 134736-12-2DP 160323-99-9DP reaction products with hyaluronic acid, prepn. of water-insol. derivs. of hyaluronic acid for use as surgical aids and drug delivery vehicles

3/7/27 (Item 7 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

116051600 CA: 116(7)51600s PATENT
Hyaluronic acid and derivatives for facilitating penetration of therapeutic agents in treatment of conditions and diseases
INVENTOR(AUTHOR): Falk, Rudolf Edgar; Asculai, Samuel S.
LOCATION: Can.,
ASSIGNEE: Norpharmco Inc.
PATENT: PCT International ; WO 9104058 A2 DATE: 910404
APPLICATION: WO 90CA306 (900918) *CA 612307 (890921)
PAGES: 116 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-047/36A
DESIGNATED COUNTRIES: AT; AU; BB; BG; BR; CA; CH; DE; DK; ES; FI; GB; HU;
JP; KP; KR; LK; LU; MC; MG; MW; NL; NO; RO; SD; SE; SU; US
DESIGNATED REGIONAL: AT; BE; BF; BJ; CF; CG; CH; CM; DE; DK; ES; FR; GA;
GB; IT; LU; ML; MR; NL; SE; SN; TD; TG
SECTION:
CA201012 Pharmacology
IDENTIFIERS: hyaluronate therapeutic penetration enhancement, cancer therapy hyaluronate tumor inhibitor, drug penetration enhancement hyaluronate
DESCRIPTORS:
Fertility...
control of, hyaluronates and therapeutic agents for, therapeutic agent penetration enhancement in relation to
Pharmaceuticals...
enhancement of penetration of, into tissue or through cell membrane,

hyaluronates for
Analgesics... Antibodies,monoclonal... Bronchodilators... Cytotoxic agents
... Diuretics... Immunosuppressants... Interferons... Interferons,.alpha.
... Interferons,.beta..... Lymphokines and Cytokines... Lymphokines and
Cytokines,interleukin 2... Neoplasm inhibitors... Nutrients,anti-...
Surfactants,anionic... Surfactants,cationic... Surfactants,nonionic...
Therapeutics,chemo-... Toxins... Virucides and Virustats...
enhancement of tissue or cell membrane penetration of, hyaluronates for
Quaternary ammonium compounds,alkylbenzyldimethyl, chlorides,biological
studies...
hyaluronate or salt or deriv. and, for treating herpes zoster,
penetration enhancement in relation to
Estrogens...
hyaluronate or salt or deriv. and, for treating post-menopause,
penetration enhancement in relation to
Pharmaceutical dosage forms...
hyaluronate-contg., for penetration enhancement
Antihypertensives... Neoplasm inhibitors,melanoma... Neoplasm
inhibitors,mesothelioma...
hyaluronates and therapeutic agents as, penetration enhancement in
relation to
Abscess... Acne... Acquired immune deficiency syndrome... Bladder,neoplasm
... Body,anatomical, back, disease, pain... Bronchi,neoplasms, carcinoma...
Edema... Infection... Mammary gland,neoplasm... Menopause,post-...
Mononucleosis... Muscle,disease, pain... Psoriasis... Respiratory
tract,disease...
hyaluronates and therapeutic agents for, penetration enhancement in
relation to
Mouth,disease, aphthous stomatitis...
hyaluronates and therapeutic agents for, therapeutic agent penetration
enhancement in relation to
Hair preparations...
hyaluronates and therapeutic agents in, for hair growth, penetration
enhancement in relation to
Pseudomonas aeruginosa... Staphylococcus aureus... Virus,animal, herpes
simplex 1... Virus,animal, herpes simplex 2...
infection by, hyaluronates and therapeutic agents for, penetration
enhancement in relation to
Virus,animal, varicella-zoster...
infection by, hyaluronates and therapeutic agents for, therapeutic
agent penetration enhancement in relation to
Proteins,specific or class, glucose-transporting...
inhibitor of, enhancement of tissue or cell membrane penetration of,
hyaluronates for
Sarcoma,epithelioid...
inhibitors, hyaluronates and therapeutic agents as, penetration
enhancement in relation to
Carcinoma,alveolar cell...
inhibitors, hyaluronates and therapeutic agents as, therapeutic agent
penetration enhancement in relation to
Inflammation inhibitors...
nonsteroidal or steroidal, enhancement of tissue or cell membrane
penetration of, hyaluronates for
Cell membrane...
of animal cell, penetration of drug through, enhancement of,
hyaluronates for
Biological transport...
of therapeutic agent, enhancement of, hyaluronate for
Bone,disease...
pain, hyaluronates and therapeutic agents for, penetration enhancement
in relation to
Animal cell... Animal tissue...
penetration of drug through, enhancement of, hyaluronate for
Organ,transplant...

rejection of, hyaluronates and therapeutic agents for, penetration enhancement in relation to

Radicals, biological studies...

scavengers of, enhancement of tissue or cell membrane penetration of, hyaluronates for

Ischemia...

vascular, hyaluronates and therapeutic agents for, penetration enhancement in relation to

CAS REGISTRY NUMBERS:

9004-61-9D analogs, therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to

67-68-5 biological studies, hyaluronate or salt or deriv. and, for treating AIDS, penetration enhancement in relation to

9004-10-8 biological studies, hyaluronate or salt or deriv. and, for treating diabetes, penetration enhancement in relation to

50-81-7 biological studies, hyaluronate or salt or deriv. and, for treating mononucleosis, penetration enhancement in relation to

9004-61-9D complexes, therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to

9004-61-9D derivs., therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to

9004-61-9D esters, therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to

106021-80-1 for gentamycin activity enhancement

137389-64-1 for increasing graft survival, penetration enhancement in relation to

137191-68-5 for treating back pain assocd. with kyphosis, penetration enhancement in relation to

137389-67-4 137389-68-5 137389-69-6 137389-70-9 137389-71-0
137389-72-1 for treating breast cancer, penetration enhancement in relation to

137459-00-8 for treating pain and infection assocd. with cervix carcinoma, penetration enhancement in relation to

137389-65-2 137458-99-2 for treating pain assocd. with adenocarcinoma, penetration enhancement in relation to

137389-66-3 for treating pain assocd. with tumor, penetration enhancement in relation to

137389-73-2 137389-74-3 137458-98-1 for treating tumor, penetration enhancement in relation to

9004-61-9D homologues, therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to

50-78-2 hyaluronate or salt or deriv. and, for enhancing prostaglandin synthesis inhibition, penetration enhancement in relation to

50-07-7 51-21-8 11056-06-7 15663-27-1 23214-92-8 41575-94-4

70476-82-3 hyaluronate or salt or deriv. and, for treating cancer, penetration enhancement in relation to

38304-91-5 hyaluronate or salt or deriv. and, for treating hair growth, penetration enhancement in relation to

26027-38-3 hyaluronate or salt or deriv. and, for treating herpes, canker sores and shingles, penetration enhancement in relation to

123-03-5 hyaluronate or salt or deriv. and, for treating herpes zoster, penetration enhancement in relation to

53-86-1 22204-53-1 74103-07-4 hyaluronate or salt or deriv. and, for treating inflammation or pain, penetration enhancement in relation to

60-81-1 60-82-2 hyaluronate or salt or deriv. and, for treating neoplasm, penetration enhancement in relation to

59-05-2 hyaluronate or salt or deriv. and, for treating psoriasis, penetration enhancement in relation to

59865-13-3 hyaluronate or salt or deriv. and, for treating rejection due to organ transplant, penetration enhancement in relation to

54-31-9 hyaluronate or salt or deriv. and, for treating renal failure, penetration enhancement in relation to

9004-61-9D salts, therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to

9004-61-9D subunit fragments, therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to
9004-61-9 therapeutic agent and, for treating diseases and conditions, therapeutic penetration enhancement in relation to
60-81-1D 5-deoxyglucuronide, hyaluronate or salt or deriv. and, for treating neoplasm, penetration enhancement in relation to

3/7/28 (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

115057253 CA: 115(6)57253g PATENT
Preparation of water-insoluble derivatives of hyaluronic acid as surgical aids and drug delivery systems
INVENTOR(AUTHOR): Burns, James W.; Cox, Steven; Walts, Alan E.
LOCATION: USA
ASSIGNEE: Genzyme Corp.
PATENT: United States ; US 5017229 A DATE: 910521
APPLICATION: US 543163 (900625)
PAGES: 6 pp. CODEN: USXXAM LANGUAGE: English CLASS: 106162000;
A61K-047/26A; C08L-001/00B
SECTION:
CA263007 Pharmaceuticals
IDENTIFIERS: hyaluronate gel surgical aid, polysaccharide modified hyaluronate tissue adhesive, matrix drug hyaluronate gel
DESCRIPTORS:
Pharmaceutical dosage forms...
matrix for, polysaccharide-modified hyaluronate gels for Medical goods...
polysaccharide-modified hyaluronate gels for, in prevention of postoperative tissue adhesion
Animal tissue...
postoperative adhesion prevention of, polysaccharide-modified hyaluronate gels for
Polysaccharides, reaction products, compounds...
with activated hyaluronates, for surgical aids and drug delivery matrixes
CAS REGISTRY NUMBERS:
9004-61-9DP 9067-32-7DP reaction products with carbodiimides and polysaccharides, prepn. of, as surgical aids and drug delivery matrixes
687-64-9DP 2133-40-6DP 2743-40-0DP 2748-02-9DP 6306-52-1DP 7517-19-3DP
7524-50-7DP 9004-32-4DP 9005-49-6DP 10466-61-2DP 12768-31-9DP
18598-74-8DP 22888-59-1DP 22888-60-4DP 24967-94-0DP 25322-46-7DP
reaction products with hyaluronate and carbodiimides, prepn. of, as surgical aids and drug delivery matrixes
1892-57-5DP 22572-40-3DP reaction products with hyaluronate and polysaccharides, prepn. of, as surgical aids and drug delivery matrixes

3/7/29 (Item 9 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

111080259 CA: 111(10)80259q PATENT
Water-insoluble biocompatible derivatives of hyaluronic acid, their manufacture and use
INVENTOR(AUTHOR): Hamilton, Raymond G.; Fox, Ellen M.; Acharya, Raksha A.; Watts, Alan E.
LOCATION: USA
ASSIGNEE: Genzyme Corp.
PATENT: PCT International ; WO 8902445 A1 DATE: 890323
APPLICATION: WO 88US2969 (880826) *US 100104 (870918)
PAGES: 24 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C08B-037/08A

DESIGNATED COUNTRIES: AU; DK; FI; JP; NO DESIGNATED REGIONAL: AT; BE; CH
; DE; FR; GB; IT; LU; NL; SE

SECTION:

CA244005 Industrial Carbohydrates

CA263XXX Pharmaceuticals

IDENTIFIERS: biocompatible hyaluronic acid amine deriv, amino acid deriv
hyaluronic acid, drug controlled release agent hyaluronamide, activator
hyaluronic acid derivatization

DESCRIPTORS:

Carbodiimides...

activators, in manuf. of hyaluronic acid amino compd. derivs.

Gels...

hyaluronic acid amino compd. deriv., biocompatible

Dyes...

hyaluronic acid amino compd. deriv. gels contg.

Amides, amino, reaction products, compounds... Amines, reaction
products, compounds... Amino acids, reaction products, compounds...

with hyaluronic acid, gels or films, biocompatible

CAS REGISTRY NUMBERS:

1892-57-5 22572-40-3 activators, in manuf. of hyaluronic acid derivs.

9067-32-7D amino acid, amide or amine deriv., biocompatible films or gels
of, as controlled-release agents or surgical aids

6104-59-2 dye, in manuf. of hyaluronic acid amino compd. deriv. gels

62-53-3D 687-51-4D 2133-40-6D 2743-40-0D 2748-02-9D 6306-52-1D

7517-19-3D 7524-50-7D 18598-74-8D 22888-59-1D 22888-60-4D
hyaluronic acid derivs., biocompatible films or gels of, as
controlled-release agents or surgical aids

? t s3/kwic/26,27

>>>KWIC option is not available in file(s): 399

? s (cd44?) (20n) (hiv or aids)

13369 CD44?

304447 HIV

216046 AIDS

S4 82 (CD44?) (20N) (HIV OR AIDS)

? rd s4

...examined 50 records (50)

...completed examining records

S5 41 RD S4 (unique items)

? t s5/3/all

5/3/1 (Item 1 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

12785314 BIOSIS NO.: 200000538937

Use of E-cadherin and CD44 aids in the differentiation between
reactive mesothelial cells and carcinoma cells in pelvic washings.

AUTHOR: Chhieng David C(a); Yee Herman; Cangiarella Joan F; Symmans W
Fraser; Cohen Jean-Marc

AUTHOR ADDRESS: (a)Department of Pathology, University of Alabama at
Birmingham, 619 19th St S, KB 526, Birmingham, AL**USA

JOURNAL: Cancer 90 (5):p299-306 October 25, 2000

MEDIUM: print

ISSN: 0008-543X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

5/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12759112 BIOSIS NO.: 200000512735
Hyaluronic acid and **CD44** aids in the differentiation between
mesothelioma from adenocarcinoma in serous effusions.
AUTHOR: Afify A(a); Michael C(a); Stern R
AUTHOR ADDRESS: (a)University of Michigan Hospital, Ann Arbor, MI**USA
JOURNAL: Laboratory Investigation 80 (3):p40A March, 2000
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the United States and Canadian
Academy of Pathology New Orleans, Louisiana, USA March 25-31, 2000
ISSN: 0023-6837
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

5/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12643889 BIOSIS NO.: 200000397391
Increased serum levels of **CD44s** and **CD44v6** in patients with
AIDS-related non-Hodgkin's lymphoma.
AUTHOR: Navarro Jose-Tomas(a); Ribera Josep-Maria(a); Vaquero Manuel;
Pastor Maria-Cruz; Oriol Albert(a); Romeu Joan; Batlle Montserrat(a);
Milla Fuensanta(a); Feliu Evarist(a)
AUTHOR ADDRESS: (a)Department of Hematology-Hemotherapy, Hospital
Universitari Germans Trias i Pujol, Universidad Autonoma de Barcelona,
Badalona**Spain
JOURNAL: AIDS (Hagerstown) 14 (10):p1460-1461 7 July, 2000
MEDIUM: print
ISSN: 0269-9370
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

5/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12344972 BIOSIS NO.: 200000098474
E-cadherin and **CD44** expression in cervical intraepithelial neoplasia:
Comparison between **HIV**-positive and **HIV**-negative women and
correlation with HPV status.
AUTHOR: Darai Emile(a); Walker-Combrouze Francine; Benifla Jean-Louis(a);
Henin Dominique; Feldmann Gerard; Madelenat Patrick(a); Scoazec Jean-Yves
AUTHOR ADDRESS: (a)Service de Gynecologie, Hopital Bichat-Claude Bernard,
Paris**France
JOURNAL: Gynecologic Oncology 76 (1):p56-62 Jan., 2000
ISSN: 0090-8258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

5/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12292783 BIOSIS NO.: 200000050650
Inhibition of thymopoiesis of CD34+ cell maturation by HIV-1 in an in vitro
CD34+ cell and thymic epithelial organ culture model.
AUTHOR: Knutson Alan P(a); Roodman Stanford T; Freeman John J; Mueller
Kathleen R; Bouhasin John D
AUTHOR ADDRESS: (a)Division of Allergy/Immunology, Pediatric Research
Institute, St. Louis University Health Sciences Center, 3662 Park Avenue,
Saint Louis, MO**USA
JOURNAL: Stem Cells (Miamisburg) 17 (6):p327-338 1999
ISSN: 1066-5099
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

5/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12076278 BIOSIS NO.: 199900371127
Alterations in blood leucocyte adhesion molecule profiles in HIV-1
infection.
AUTHOR: Hayes P J(a); Miao Y M; Gotch F M; Gazzard B G
AUTHOR ADDRESS: (a)Department of Immunology, Chelsea and Westminster
Hospital, 369 Fulham Road, London, SW10 9NH**UK
JOURNAL: Clinical and Experimental Immunology 117 (2):p331-334 Aug., 1999
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

5/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11878986 BIOSIS NO.: 199900125095
Altered expression of CD4, CD54, CD62L, and CCR5 in primary lymphocytes
productively infected with the human immunodeficiency virus.
AUTHOR: Marodon Gilles; Landua Nathaniel R; Posnett David N(a)
AUTHOR ADDRESS: (a)CUMC, 1300 York Ave., Box 56, New York, NY 10021**USA
JOURNAL: AIDS Research and Human Retroviruses 15 (2):p161-171 Jan. 20,
1999
ISSN: 0889-2229
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11037952 BIOSIS NO.: 199799659097
Expression of cell adhesion molecules at the surface of in vitro human
immunodeficiency virus type 1-infected human monocytes: Relationships
with tumor necrosis factor alpha, interleukin 1-beta, and interleukin 6
syntheses.
AUTHOR: Le Naour Richard(a); Lussiez Caroline; Raoul Herve; Mabondzo Aloise
; Dormont Dominique
AUTHOR ADDRESS: (a)Serv. de Neurovirologie, CEA/DSV/DRM, Cent. d'Etudes

Nucleaires de Fontenay aux Roses, B.P. 6, 6**France
JOURNAL: AIDS Research and Human Retroviruses 13 (10):p841-855 1997
ISSN: 0889-2229
RECORD TYPE: Abstract
LANGUAGE: English

5/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10866392 BIOSIS NO.: 199799487537
Overexpression of JUN and BCL-2 proteins is universal in Kaposi's sarcoma lesions, whereas HSP72, ubiquitin, and CD44 staining patterns differ according to HIV infection status and evolutionary stage.
AUTHOR: Puig L(a); Fernandez-Figueras M T; Alegre M(a); Esquius M; Ferrandiz C
AUTHOR ADDRESS: (a)Dep. Dermatol., Hosp. Santa Creu i Sant Pau, Barcelona** Spain
JOURNAL: Journal of Cutaneous Pathology 24 (2):p117 1997
CONFERENCE/MEETING: 34th Annual Meeting of the American Society of Dermatopathology San Francisco, California, USA March 18-20, 1997
ISSN: 0303-6987
RECORD TYPE: Citation
LANGUAGE: English

5/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10699616 BIOSIS NO.: 199799320761
Alteration of CD44 expression in HIV type 1-infected T cell lines.
AUTHOR: Giordanengo Valerie; Limouse Martine; Doglio Alain; Lesimple Josette; Lefebvre Jean-Claude(a)
AUTHOR ADDRESS: (a)Lab. Virol., Fac. Med., Avenue Valombrose, 06107 Nice cedex 2**France
JOURNAL: AIDS Research and Human Retroviruses 12 (17):p1615-1622 1996
ISSN: 0889-2229
RECORD TYPE: Abstract
LANGUAGE: English

5/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10468259 BIOSIS NO.: 199699089404
Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway.
AUTHOR: Shattock Robin J(a); Rizzardi Gian Paolo; Hayes Peter; Griffin George E
AUTHOR ADDRESS: (a)Div. Infect. Dis., St. George's Hosp. Med. Sch., Cranmer Terrace, SW17 0RE London**UK
JOURNAL: Journal of Infectious Diseases 174 (1):p54-62 1996
ISSN: 0022-1899
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/12 (Item 12 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10452830 BIOSIS NO.: 199699073975

Regulation of CD18, **CD44** and ICAM-1 expression on **HIV-1**
infected human monocytes is dependent on endogenous TNF-alpha production.

AUTHOR: Le Naour R; Lussicz C; Raoul H; Mabondzo A; Dormont D

AUTHOR ADDRESS: Serv. Neurovirol., DSV/DRM, CRSSA, IPSC, CEA, 92265
Fontenay aux Roses Cedex**France

JOURNAL: European Cytokine Network 7 (2):p262 1996

CONFERENCE/MEETING: 6th International Tumor Necrosis Factor Congress
Rhodes, Greece May 8-12, 1996

ISSN: 1148-5493

RECORD TYPE: Citation

LANGUAGE: English

5/3/13 (Item 13 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10241497 BIOSIS NO.: 199698696415

In vitro culture of human peripheral blood monocytes induces hyaluronan
binding and up-regulates monocyte variant CD44 isoform expression.

AUTHOR: Levesque Marc C(a); Haynes Barton F

AUTHOR ADDRESS: (a)Box 3258, Duke University Medical Center, Durham, NC
27710**USA

JOURNAL: Journal of Immunology 156 (4):p1557-1565 1996

ISSN: 0022-1767

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

5/3/14 (Item 14 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10179740 BIOSIS NO.: 199698634658

HIV acquires functional adhesion receptors from host cells.

AUTHOR: Guo Margaret M Lee; Hildreth James E K(a)

AUTHOR ADDRESS: (a)Leukocyte Immunochemistry Lab., Dep. Pharmacology
Molecular Sciences, Johns Hopkins Univ. Sch. M**USA

JOURNAL: AIDS Research and Human Retroviruses 11 (9):p1007-1013 1995

ISSN: 0889-2229

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

5/3/15 (Item 15 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10014628 BIOSIS NO.: 199598469546

Inhibition of **HIV** type 1 infection of mononuclear phagocytes by anti-
CD44 antibodies.

AUTHOR: Rivadeneira Emilia D; Sauls Derrick L; Yu Yinhua; Haynes Barton F;
Weinberg J Brice(a)

AUTHOR ADDRESS: (a)VA Duke Med. Cent., 508 Fulton St., Durham, NC 27705**
USA

JOURNAL: AIDS Research and Human Retroviruses 11 (5):p541-546 1995

ISSN: 0889-2229

DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

5/3/16 (Item 16 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09906572 BIOSIS NO.: 199598361490
Cellular CD44S as a determinant of human immunodeficiency virus type 1
infection and cellular tropism.
AUTHOR: Dukes Carol S; Yu Yinhua; Rivadeneira Emilia D; Sauls Derrick L;
Liao Hua-Xin; Haynes Barton F; Weinberg J Brice(a)
AUTHOR ADDRESS: (a)VA Med. Cent., 508 Fulton St., Durham, NC 27705**USA
JOURNAL: Journal of Virology 69 (7):p4000-4005 1995
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/17 (Item 17 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09132369 BIOSIS NO.: 199497140739
Peripheral T lymphocyte depletion by apoptosis after CD4 ligation in vivo:
Selective loss of CD44- and 'activating' memory T cells.
AUTHOR: Howie S E M(a); Sommerfield A J; Gray E; Harrison D J
AUTHOR ADDRESS: (a)Dep. Pathol., Edinburgh Univ. Med. Sch., Teviot Place,
Edinburgh EH8 9AG**UK
JOURNAL: Clinical and Experimental Immunology 95 (1):p195-200 1994
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/18 (Item 18 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09082798 BIOSIS NO.: 199497091168
Association of host cell surface adhesion receptors and other membrane
proteins with HIV and SIV.
AUTHOR: Orentas Rimas J; Hildreth James E K(a)
AUTHOR ADDRESS: (a)Leukocyte Immunochem. Lab., Johns Hopkins Univ. Sch.
Med., Dep. Pharmacol. and Molecular Sci., 7**USA
JOURNAL: AIDS Research and Human Retroviruses 9 (11):p1157-1165 1993
ISSN: 0889-2229
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/19 (Item 19 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08960737 BIOSIS NO.: 199396112238
HIV-induced loss of CD44 expression in monocytic cell lines.
AUTHOR: Guo Margaret M Lee; Hildreth James E K(a)
AUTHOR ADDRESS: (a)Leukocyte Immunochem. Lab., Dep. Pharmacol. and Mol.
Sci., Johns Hopkins Univ. Sch. Med., 725 No**USA

JOURNAL: Journal of Immunology 151 (4):p2225-2236 1993
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08593865 BIOSIS NO.: 199345011940
Differential modulation of **HIV-1** infection of a T cell line by
expression of transfected **CD44E** and **CD44H** isoforms.
AUTHOR: Rivadeneira E D(a); Liao H-X; Sauls D L; Haynes B F; Weinberg J B
AUTHOR ADDRESS: (a)VA Univ. Med. Cent., Durham, NC**USA
JOURNAL: Clinical Research 41 (2):p322A 1993
CONFERENCE/MEETING: Joint Meeting of the Association of American
Physicians, the American Society for Clinical Investigation, and the
American Federation for Clinical Research Washington, DC, USA April
30-May 3, 1993
ISSN: 0009-9279
RECORD TYPE: Citation
LANGUAGE: English

5/3/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08219819 BIOSIS NO.: 000043019667
HIV-1 INFECTION OF HUMAN MONOCYTES THE ROLE OF THE HYALURONATE
RECEPTOR **CD44**
AUTHOR: RIVADENEIRA E D; MATTHEWS T J; HAYNES B F; WEINBERG J B
AUTHOR ADDRESS: V.A. MED. CENT., DURHAM, N.C. 27705.
JOURNAL: KEYSTONE SYMPOSIUM ON PREVENTION AND TREATMENT OF AIDS, KEYSTONE,
COLORADO, USA, MARCH 27-APRIL 3, 1992. J CELL BIOCHEM SUPPL 0 (16 PART E).
1992. 100. 1992
CODEN: JCBSD
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

5/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08133888 BIOSIS NO.: 000093121036
BIOCHEMICAL AND MORPHOLOGICAL DIFFERENTIATION OF THE HUMAN COLONIC
EPITHELIAL CELL LINE SW620 IN THE PRESENCE OF DIMETHYLSULFOXIDE
AUTHOR: OMARY M B; DE GRANDPRE L; MCCAFFREY M; KAGNOFF M F
AUTHOR ADDRESS: DEP. MED., STANFORD UNIV. SCH. MED., ROOM S-069, STANFORD,
CALIF. 94305.
JOURNAL: J CELL BIOCHEM 48 (3). 1992. 316-323. 1992
FULL JOURNAL NAME: Journal of Cellular Biochemistry
CODEN: JCEBD
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

5/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

07740888 BIOSIS NO.: 000041049684
POSSIBLE ROLE OF THE HYALURONATE RECEPTOR **CD44** IN THE IN-VITRO
INFECTION OF HUMAN MONOCYTES WITH **HIV-1**
AUTHOR: RIVADENEIRA E D; MATTHEWS T J; HAYNES B F; WEINBERG J B
AUTHOR ADDRESS: VA AND DUKE UNIV. MED. CENT., DURHAMS, N.C.
JOURNAL: JOINT MEETING OF THE ASSOCIATION OF AMERICAN PHYSICIANS, THE
AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, AND THE AMERICAN FEDERATION
FOR CLINICAL RESEARCH, SEATTLE, WASHINGTON, USA, MAY 3-6, 1991. CLIN RES 39
(2). 1991. 382A. 1991
CODEN: CLREA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

5/3/24 (Item 24 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

07522247 BIOSIS NO.: 000091085376
NON-MITOGENIC T CELL ACTIVATION SIGNALS ARE SUFFICIENT FOR INDUCTION OF
HUMAN IMMUNODEFICIENCY VIRUS TRANSCRIPTION
AUTHOR: GRUTERS R A; OTTO S A; AL B J M; VERHOEVEN A J; VERWEIJ C L; VAN
LIER R A W; MIEDEMA F
AUTHOR ADDRESS: CENTRAL LAB. NETHERLANDS RED CROSS BLOOD TRANSFUSION SERV.,
P.O. BOX 9406, NL-1006 AK AMSTERDAM, NETHERLANDS.
JOURNAL: EUR J IMMUNOL 21 (1). 1991. 167-172. 1991
FULL JOURNAL NAME: European Journal of Immunology
CODEN: EJIMA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

5/3/25 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

10515460 EMBASE No: 1999426779
Inhibition of thymopoiesis of CD34^{sup} + cell maturation by HIV-1 in an in
vitro CD34^{sup} + cell and thymic epithelial organ culture model
Knutson A.P.; Roodman S.T.; Freeman J.J.; Mueller K.R.; Bouhasin J.D.
Dr. A.P. Knutson, Division of Allergy/Immunology, Pediatric Research
Institute, St. Louis Univ. Hlth. Sci. Center, 3662 Park Avenue, St.
Louis, MO 63110 United States
Stem Cells (STEM CELLS) (United States) 1999, 17/6 (327-338)
CODEN: STCEE ISSN: 1066-5099
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 42

5/3/26 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

06719036 EMBASE No: 1997000505
Alteration of **CD44** expression in **HIV** type 1-infected T cell
lines
J.-C. Lefebvre, Laboratoire de Virologie, Faculte de Medecine, Avenue de
Valombrose, 06107 Nice Cedex 2
AIDS Research and Human Retroviruses (AIDS RES. HUM. RETROVIRUSES) (United States) 1996, 12/17 (1615-1622)
CODEN: ARHRE ISSN: 0889-2229

DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

5/3/27 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

05799048 EMBASE No: 1994190040
Peripheral T lymphocyte depletion by apoptosis after CD4 ligation in vivo: Selective loss of CD44^{sup} - and 'activating' memory T cells
Howie S.E.M.; Sommerfield A.J.; Gray E.; Harrison D.J.
Department of Pathology, Edinburgh University Medical School, Teviot Place, Edinburgh EH8 9AG United Kingdom
Clinical and Experimental Immunology (CLIN. EXP. IMMUNOL.) (United Kingdom) 1994, 95/1 (195-200)
CODEN: CEXIA ISSN: 0009-9104
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

5/3/28 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10240981 99380593 PMID: 10449768
Ligation of the CD4 receptor induces activation-independent down-regulation of L-selectin.
Marschner S; Freiberg BA; Kupfer A; Hunig T; Finkel TH
Division of Basic Sciences, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.
Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 17 1999, 96 (17) p9763-8, ISSN 0027-8424
Journal Code: PV3
Contract/Grant No.: RO1 AI 40003, AI, NIAID; RO1 AI23764D, AI, NIAID; RO1 AI35513, AI, NIAID
Languages: ENGLISH
Document type: Journal Article
Record type: Completed

5/3/29 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09136477 97103689 PMID: 8948027
Development of a method of thymocyte differentiation of bone marrow-enriched CD34+CD38- cells in postnatal allogeneic cultured thymic epithelia to evaluate immunodeficiency disorders.
Knutsen AP; Roodman ST; Ruiz ME; Mueller KR; Bouhasin JD
Pediatric Research Institute, St. Louis University Health Sciences Center, Missouri 63110, USA.
Stem cells (UNITED STATES) Nov 1996, 14 (6) p702-13, ISSN 1066-5099
Journal Code: BN2
Languages: ENGLISH
Document type: Journal Article
Record type: Completed

5/3/30 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08386397 95194624 PMID: 7534091
Treatment of HIV-infected fibroblasts with human leukocyte antigen (HLA)-DR-inductive cytokines leads to infectious virions with newly acquired HLA-DR.

Capobianchi MR; Serra C; Abbate I; Marongiu P; Castilletti C; Tilocca F;
Dianzani F; Dolei A
AIDS (UNITED STATES) Dec 1994, 8 (12) p1731-3, ISSN 0269-9370
Journal Code: AID
Languages: ENGLISH
Document type: Letter
Record type: Completed

5/3/31 (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134202678 CA: 134(15)202678y PATENT
Sequences of human genes involving in HIV replication and uses thereof in
therapy and drug screening
INVENTOR(AUTHOR): Holzmayer, Tanya A.; Dunn, Stephen J.
LOCATION: USA
ASSIGNEE: Subsidiary No. 3, Inc.
PATENT: PCT International ; WO 200116322 A2 DATE: 20010308
APPLICATION: WO 2000US24262 (20000901) *US 388182 (19990901)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/12A;
C12N-005/10B; C07K-014/47B; A61K-038/17B; A61K-031/70B; G01N-033/50B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;
SE; BF; BJ; CF; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3/32 (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

133175528 CA: 133(13)175528v JOURNAL
Expression of Epstein-Barr virus latent genes and adhesion molecules in
AIDS-related non-Hodgkin's lymphomas. Correlation with histology and
CD4-cell number
AUTHOR(S): Kersten, M. J.; Van Gorp, J.; Pals, S. T.; Boon, F.; Van Oers,
M. H. J.
LOCATION: Department of Hematology, Academic Medical Center, Amsterdam,
Neth.
JOURNAL: Leuk. Lymphoma DATE: 1998 VOLUME: 30 NUMBER: 5/6 PAGES:
515-524 CODEN: LELYEA ISSN: 1042-8194 LANGUAGE: English PUBLISHER:
Harwood Academic Publishers

5/3/33 (Item 3 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

130137881 CA: 130(11)137881k JOURNAL
Role of cellular adhesion molecules in HIV type 1 infection and their
impact on virus neutralization
AUTHOR(S): Hioe, Catarina E.; Bastiani, Lisa; Hildreth, James E. K.;
Zolla-Pazner, Susan
LOCATION: Department of Pathology, New York University Medical Center and
Manhattan VA Medical Center, New York, NY, 10010, USA
JOURNAL: AIDS Res. Hum. Retroviruses DATE: 1998 VOLUME: 14 NUMBER:
Suppl. 3 PAGES: S247-S254 CODEN: ARHRE7 ISSN: 0889-2229 LANGUAGE:
English PUBLISHER: Mary Ann Liebert, Inc.

5/3/34 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

130047465 CA: 130(5)47465y PATENT
Compositions and methods for inhibiting HIV infection by down-regulating
human cellular genes
INVENTOR(AUTHOR): Holzmayer, Tanya A.; Dunn, Stephen J.; Dayn, Andrew
LOCATION: USA
ASSIGNEE: Subsidiary No. 3, Inc.
PATENT: PCT International ; WO 9854366 A1 DATE: 19981203
APPLICATION: WO 98US11452 (19980602) *US 867314 (19970602)
PAGES: 85 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;
C12N-015/00B; C12N-015/11B; C12N-015/85B; C12P-019/34B; A61K-048/00B;
C07H-021/04B DESIGNATED COUNTRIES: AL; AM; AU; AZ; BA; BB; BG; BR; BY; CA;
CN; CU; CZ; EE; GE; GW; HU; ID; IL; IS; JP; KG; KP; KR; KZ; LC; LK; LR;
LT; LV; MD; MG; MN; MX; NO; NZ; PL; RO; RU; SG; SI; SK; SL; TJ; TM; TR;
TT; UA; UZ; VN; YU; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY;
DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
CM; GA; GN; ML; MR; NE; SN; TD; TG

5/3/35 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

129107901 CA: 129(9)107901d CONFERENCE PROCEEDING
Monocyte adhesion regulates HIV transcription
AUTHOR(S): Shattock, R. J.; Griffin, G. E.
LOCATION: Division of Infectious Diseases, St George's Hospital Medical
School, Tooting, UK,
JOURNAL: HIV Cytokines EDITOR: Guenounou, Moncef (Ed), DATE: 1997
PAGES: 49-59 CODEN: 66AJA9 LANGUAGE: English PUBLISHER: Editions
INSERM, Paris, Fr

5/3/36 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

128319071 CA: 128(26)319071n PATENT
Growth of B cell lymphomas on HIV-infected endothelial cells
INVENTOR(AUTHOR): Nelson, Jay; Moses, Ashlee; Bagby, Grover
LOCATION: USA
ASSIGNEE: Oregon Health Sciences University; Nelson, Jay; Moses, Ashlee;
Bagby, Grover
PATENT: PCT International ; WO 9818004 A1 DATE: 19980430
APPLICATION: WO 97US19323 (19971023) *US 29605 (19961024)
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: G01N-033/53A;
C12P-021/06B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY;
CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; HU; ID; IL; IS; JP; KE;
KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ;
PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN;
YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; KE; LS;
MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

5/3/37 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

128139683 CA: 128(12)139683e JOURNAL
Phenotypic changes of monocytes induced by HIV-1 GP120 molecule and its
fragments.
AUTHOR(S): Zembala, Marek; Bach, Simona; Szczepanek, A.; Mancino, Giorgio
; Colizzi, Vittorio
LOCATION: Department of Clinical Immunology, Institute of Paediatrics,
Jagiellonian University, Krakow, Pol.
JOURNAL: Immunobiology DATE: 1997 VOLUME: 197 NUMBER: 1 PAGES:
110-121 CODEN: IMMND4 ISSN: 0171-2985 LANGUAGE: English PUBLISHER:
Gustav Fischer Verlag

5/3/38 (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

126304859 CA: 126(23)304859k JOURNAL
Host cell-dependent alterations in envelope components of human
immunodeficiency virus type 1 virions
AUTHOR(S): Bastiani, Lisa; Laal, Suman; Kim, Mimi; Zolla-Pazner, Susan
LOCATION: Dep. Pathology, NYU Medical Center, New York, NY, 10016, USA
JOURNAL: J. Virol. DATE: 1997 VOLUME: 71 NUMBER: 5 PAGES: 3444-3450
CODEN: JOVIAM ISSN: 0022-538X LANGUAGE: English PUBLISHER: American
Society for Microbiology

5/3/39 (Item 9 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

126169852 CA: 126(13)169852k JOURNAL
Evaluation of the adrenal gland functional reserve in patients affected
by HIV infection
AUTHOR(S): Cinquanta, L.; Boffa, N.; D'Aiuto, V.; Vicinanza, P.
LOCATION: Department of Laboratory Medicine, S. Giovanni di Dio e G.
Ruggi d'Aragona Hospital, 84100, Salerno, Italy
JOURNAL: Eur. J. Lab. Med. DATE: 1996 VOLUME: 4 NUMBER: 2 PAGES:
106-111 CODEN: EJLAEW ISSN: 1122-8652 LANGUAGE: English PUBLISHER:
Societa Italiana di Medicina di Laboratorio

5/3/40 (Item 10 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

125084393 CA: 125(7)84393r DISSERTATION
The role of CD44 in HIV infection (monocytes, adhesion, immune
deficiency, hyaluronic acid)
AUTHOR(S): Guo, Margaret Ming-Ti
LOCATION: Johns Hopkins Univ., Baltimore, MD, USA
DATE: 1996 PAGES: 198 pp. CODEN: DABBBA LANGUAGE: English CITATION:
Diss. Abstr. Int., B 1996, 57(1), 225 AVAIL: Univ. Microfilms Int., Order
No. DA9617526

5/3/41 (Item 11 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

117003845 CA: 117(1)3845z PATENT
CD44 as a marker for AIDS
INVENTOR(AUTHOR): Landay, Alan
LOCATION: USA

PATENT: United States ; US 5108904 A DATE: 920428
APPLICATION: US 499144 (900326)
PAGES: 7 pp. CODEN: USXXAM LANGUAGE: English CLASS: 435007240;
G01N-033/533A
?

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 31 returned.**

1. Document ID: JP 09183804 A

L1: Entry 1 of 31

File: JPAB

Jul 15, 1997

PUB-NO: JP409183804A

DOCUMENT-IDENTIFIER: JP 09183804 A

TITLE: WATER-INSOLUBLE DERIVATIVE OF HYALURONIC ACID

PUBN-DATE: July 15, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
HAMILTON, RAYMOND G	
FOX, ELLEN M	
ACHARYA, RAKSHA A	
WALTS, ALAN E	

INT-CL (IPC): C08 B 37/08; A61 L 15/44[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

2. Document ID: JP 08217680 A

L1: Entry 2 of 31

File: JPAB

Aug 27, 1996

PUB-NO: JP408217680A

DOCUMENT-IDENTIFIER: JP 08217680 A

TITLE: AIDS INFECTION PREVENTING LUBRICANT

PUBN-DATE: August 27, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
KANAMARU, EIJI	
MORITA, MITSUYA	
ENOMOTO, YUTAKA	
YAMAMOTO, NAOKI	

INT-CL (IPC): A61 K 31/725; A61 K 9/06[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

3. Document ID: JP 08151328 A

L1: Entry 3 of 31

File: JPAB

Jun 11, 1996

PUB-NO: JP408151328A

DOCUMENT-IDENTIFIER: JP 08151328 A

TITLE: LUBRICATING AGENT FOR PREVENTING INFECTION OF AIDS

PUBN-DATE: June 11, 1996

INVENTOR-INFORMATION:

NAME

COUNTRY

ENOMOTO, YUTAKA

KANAMARU, EIJI

MORITA, MITSUYA

YAMAMOTO, NAOKI

INT-CL (IPC): A61 K 31/725; A61 K 9/06; A61 K 35/80; A61 K 47/36

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Drawn Desc](#) [Image](#)

4. Document ID: JP 01319427 A

L1: Entry 4 of 31

File: JPAB

Dec 25, 1989

PUB-NO: JP401319427A

DOCUMENT-IDENTIFIER: JP 01319427 A

TITLE: SUPEROXIDE DISMUTASE-CONTAINING PHARMACEUTICAL COMPOSITION FOR LOCAL ADMINISTRATION

PUBN-DATE: December 25, 1989

INVENTOR-INFORMATION:

NAME

COUNTRY

HOSHI, KEIKO

YANAGAWA, AKIRA

MIZUSHIMA, YUTAKA

NIWA, YUKIE

INT-CL (IPC): A61K 37/52

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Drawn Desc](#) [Image](#)

5. Document ID: JP 01221308 A

L1: Entry 5 of 31

File: JPAB

Sep 4, 1989

PUB-NO: JP401221308A

DOCUMENT-IDENTIFIER: JP 01221308 A

TITLE: HAIR COSMETIC AND PRODUCTION THEREOF

PUBN-DATE: September 4, 1989

INVENTOR-INFORMATION:

NAME	COUNTRY
YOSHIKAWA, SATOSHI	
AKIMOTO, KUMIKO	
HIRAKI, YOSHIO	

INT-CL (IPC): A61K 7/06; A61K 7/08

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KWC](#) [Draw Desc](#) [Image](#)

6. Document ID: US 5879359 A

L1: Entry 6 of 31

File: EPAB

Mar 9, 1999

PUB-NO: US005879359A

DOCUMENT-IDENTIFIER: US 5879359 A

TITLE: Biodegradable guide channels comprised of esters of hyaluronic acid for use in tissue repair as surgical aids

PUBN-DATE: March 9, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
DORIGATTI, FRANCO	IT
FAVARO, GIORGIO	IT
CALLEGARO, LANFRANCO	IT
ROMEO, AURELIO	IT

INT-CL (IPC): A61 B 17/08

EUR-CL (EPC): A61L031/00; A61F002/02, A61L031/00, A61L031/00

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KWC](#) [Draw Desc](#) [Image](#)

7. Document ID: WO 9839015 A1

L1: Entry 7 of 31

File: EPAB

Sep 11, 1998

PUB-NO: WO009839015A1

DOCUMENT-IDENTIFIER: WO 9839015 A1

TITLE: OPHTHALMIC COMPOSITION

PUBN-DATE: September 11, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
FERGEUS, SUSANNA	
LUNDBERG, KERSTIN	
WIK, OVE	

INT-CL (IPC): A61 K 31/725; A61 K 31/73; A61 K 9/00

EUR-CL (EPC): A61K031/715

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KWC](#) [Draw Desc](#) [Image](#)

8. Document ID: US 5677276 A

L1: Entry 8 of 31

File: EPAB

Oct 14, 1997

PUB-NO: US005677276A
DOCUMENT-IDENTIFIER: US 5677276 A
TITLE: Immobilization of peptides to hyaluronate

PUBN-DATE: October 14, 1997

INVENTOR- INFORMATION:

NAME	COUNTRY
DICKERSON, KENNETH T	US
GLASS, JAMES R	US
LIU, LIN-SHU	US
POLAREK, JAMES W	US
CRAIG, WILLIAM S	US
MULLEN, DANIEL G	US
CHENG, SOAN	US

INT-CL (IPC) : A61 K 38/08; A61 K 38/10; A61 K 38/14; C07 K 1/113
EUR-CL (EPC) : C07K001/107; C07K014/78

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)

 9. Document ID: WO 9620002 A1

L1: Entry 9 of 31

File: EPAB

Jul 4, 1996

PUB-NO: WO009620002A1
DOCUMENT-IDENTIFIER: WO 9620002 A1
TITLE: IMMobilization OF PEPTIDES TO HYALURONATE

PUBN-DATE: July 4, 1996

INVENTOR- INFORMATION:

NAME	COUNTRY
DICKERSON, KENNETH T	
GLASS, JAMES R	
LIU, LIN-SHU	
POLAREK, JAMES W	
CRAIG, WILLIAM S	
MULLEN, DANIEL G	
CHENG, SOAN	

INT-CL (IPC) : A61 K 38/03; A61 K 38/08; A61 K 38/10; A61 K 38/14; C07 K 1/113; C07 K 4/00; C07 K 7/06; C07 K 7/08; C07 K 9/00
EUR-CL (EPC) : C07K001/107; C07K014/00, C07K014/78

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)

 10. Document ID: US 5502081 A

L1: Entry 10 of 31

File: EPAB

Mar 26, 1996

PUB-NUM: US005502081A

DOCUMENT-IDENTIFIER: US 5502081 A

TITLE: Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use

PUBN-DATE: March 26, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
KUO, JING-WEN	US
SWANN, DAVID A	US
PRESTWICH, GLENN D	US

INT-CL (IPC): A61 K 47/36; A61 K 9/70; A01 N 25/10; A61 L 15/28

EUR-CL (EPC): A61K047/36; A61K047/48, A61L027/00, A61L031/00, C08B037/00, A61K047/48

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)
[KWC](#) [Drawn Desc](#) [Image](#)
[Generate Collection](#)
[Print](#)

Term	Documents
HYALURON\$	0
HYALURON.DWPI,EPAB,JPAB.	7
HYALURONAD.DWPI,EPAB,JPAB.	1
HYALURONAK.DWPI,EPAB,JPAB.	1
HYALURONAN.DWPI,EPAB,JPAB.	102
HYALURONANE.DWPI,EPAB,JPAB.	2
HYALURONANS.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIAT.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIATED.DWPI,EPAB,JPAB.	3
HYALURONAN-BASED.DWPI,EPAB,JPAB.	1
HYALURONAN-BINDING.DWPI,EPAB,JPAB.	5
((HYALURON\$) SAME (HIV OR AIDS)).JPAB,EPAB,DWPI.	31

[There are more results than shown above. Click here to view the entire set.](#)

Display Format: [CIT](#) [Change Format](#)

[Previous Page](#) [Next Page](#)

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 11 through 20 of 31 returned.

11. Document ID: US 5356883 A

L1: Entry 11 of 31

File: EPAB

Oct 18, 1994

PUB-NO: US005356883A

DOCUMENT-IDENTIFIER: US 5356883 A

TITLE: Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use

PUBN-DATE: October 18, 1994

INVENTOR- INFORMATION:

NAME	COUNTRY
KUO, JING-WEN	US
SWANN, DAVID A	US
PRESTWICH, GLENN D	US

INT-CL (IPC): A61K 31/725; A61K 31/735; A61K 47/26; C08L 1/00

EUR-CL (EPC): A61K047/36; A61K047/48, A61L027/00, A61L031/00, C08B037/00, A61K047/48

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)

12. Document ID: WO 9402517 A1

L1: Entry 12 of 31

File: EPAB

Feb 3, 1994

PUB-NO: WO009402517A1

DOCUMENT-IDENTIFIER: WO 9402517 A1

TITLE: WATER-INSOLUBLE DERIVATIVES OF HYALURONIC ACID AND THEIR METHODS OF PREPARATION AND USE

PUBN-DATE: February 3, 1994

INVENTOR- INFORMATION:

NAME	COUNTRY
KUO, JING-WEN	
SWANN, DAVID A	
PRESTWICH, GLENN D	

US-CL-CURRENT: 536/123.1; 536/126

INT-CL (IPC): C08B 37/08; A61K 47/36; A61L 31/00

EUR-CL (EPC): A61K047/36; A61L031/00, C08B037/00, A61K047/48, A61K047/48

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)

13. Document ID: EP 399156 A1

L1: Entry 13 of 31

File: EPAB

Nov 28, 1990

PUB-NO: EP000399156A1
 DOCUMENT-IDENTIFIER: EP 399156 A1
 TITLE: Sodium hyaluronate composition.

PUBN-DATE: November 28, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
SWANN, DAVID A	US
SULLIVAN, BERNARD P	US
DEVORE, DALE P	US

INT-CL (IPC): A61L 31/00; A61K 9/06; A61K 31/73
 EUR-CL (EPC): A61K031/73

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

 14. Document ID: WO 9006767 A1

L1: Entry 14 of 31

File: EPAB

Jun 28, 1990

PUB-NO: WO009006767A1
 DOCUMENT-IDENTIFIER: WO 9006767 A1
 TITLE: POLYPEPTIDE-POLYMER CONJUGATES ACTIVE IN WOUND HEALING

PUBN-DATE: June 28, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
PIERSCHBACHER, MICHAEL D	US
POLAREK, JAMES W	US
PETRICA, MARIANNE P	US
RUOSLAHTI, ERKKI I	US

INT-CL (IPC): A61K 37/02; A61K 47/48; C07K 7/04; C07K 17/02
 EUR-CL (EPC): A61K047/48; A61L025/00, C07K007/06, C07K007/08, C08B037/00, A61K038/39, C07K014/78

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

 15. Document ID: EP 1165112 A1, WO 200057896 A1, AU 200040255 A

L1: Entry 15 of 31

File: DWPI

Jan 2, 2002

DERWENT-ACC-NO: 2000-672524

DERWENT-WEEK: 200209

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Novel composition useful as inhibitor or enhancer of glycosaminoglycan-mediated processes, for treating or preventing infections, inflammatory diseases and cancers

INVENTOR: MOHAMADZADEH, M; MUMMERT, M E ; TAKASHIMA, A

PRIORITY-DATA: 1999US-126475P (March 26, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1165112 A1	January 2, 2002	E	000	A61K038/00
WO 200057896 A1	October 5, 2000	E	053	A61K038/00
AU 200040255 A	October 16, 2000		000	A61K038/00

INT-CL (IPC): A61 K 38/00; A61 K 38/03; A61 K 38/16
[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)
[KIMC](#) [Drawn Desc](#) [Clip Img](#) [Image](#)
 16. Document ID: EP 1140198 A1, WO 200041730 A1, AU 200024231 A

L1: Entry 16 of 31

File: DWPI

Oct 10, 2001

DERWENT-ACC-NO: 2000-491026

DERWENT-WEEK: 200167

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Enhancing the effectiveness of a cytotoxic or anti-neoplastic agent e.g. methotrexate or 5-fluorouracil, comprises co-administration with hyaluronan

INVENTOR: BROWN, T

PRIORITY-DATA: 1999AU-0003938 (November 9, 1999), 1999AU-0008131 (January 13, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1140198 A1	October 10, 2001	E	000	A61K047/36
WO 200041730 A1	July 20, 2000	E	126	A61K047/36
AU 200024231 A	August 1, 2000		000	A61K047/36

INT-CL (IPC): A61 K 47/36; A61 P 35/00
[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)
[KIMC](#) [Drawn Desc](#) [Image](#)
 17. Document ID: CN 1215060 A

L1: Entry 17 of 31

File: DWPI

Apr 28, 1999

DERWENT-ACC-NO: 1999-405801

DERWENT-WEEK: 199936

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Powdery transparent acid making method and crystallisation tank thereof

INVENTOR: LI, Z

PRIORITY-DATA: 1998CN-0110455 (September 16, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1215060 A	April 28, 1999		000	C08B037/08

INT-CL (IPC): C08 B 37/08
[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)
[KIMC](#) [Drawn Desc](#) [Image](#)

18. Document ID: JP 2001510707 W, DE 29801281 U1, WO 9904729 A1, AU 9884594 A, EP 1011538 A1, US 6136026 A

L1: Entry 18 of 31

File: DWPI

Aug 7, 2001

DERWENT-ACC-NO: 1998-195087

DERWENT-WEEK: 200150

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Intraocular arrangement for implanting lens in a human eye - comprising ring of biologically compatible material suppressing cell growth

INVENTOR: ISRAEL, H; ISRAEL, H M

PRIORITY-DATA: 1997IL-0121417 (July 28, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2001510707 W	August 7, 2001		016	A61F002/16
DE 29801281 U1	March 26, 1998		018	A61F002/14
WO 9904729 A1	February 4, 1999	E	000	A61F002/16
AU 9884594 A	February 16, 1999		000	A61F002/16
EP 1011538 A1	June 28, 2000	E	000	A61F002/16
US 6136026 A	October 24, 2000		000	A61F002/14

INT-CL (IPC): A61 F 2/14; A61 F 2/16; A61 F 9/00
[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)
[KWD](#) | [Draw Desc](#) | [Clip Img](#) | [Image](#)

19. Document ID: JP 2000512484 W, WO 9738098 A1, AU 9722841 A, EP 894131 A1

L1: Entry 19 of 31

File: DWPI

Sep 26, 2000

DERWENT-ACC-NO: 1997-512715

DERWENT-WEEK: 200051

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Isolated human receptor for hyaluronic acid mediated motility - used to develop products for treating e.g. tumours, inflammatory disorders, dementia, AIDS, diabetes and auto-immune diseases

INVENTOR: ENTWISTLE, J; TURLEY, E A

PRIORITY-DATA: 1996GB-0007441 (April 10, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2000512484 W	September 26, 2000		060	C12N015/09
WO 9738098 A1	October 16, 1997	E	066	C12N015/12
AU 9722841 A	October 29, 1997		000	C12N015/12
EP 894131 A1	February 3, 1999	E	000	C12N015/12

INT-CL (IPC): A01 K 67/027; A61 K 31/00; A61 K 31/70; A61 K 48/00; C07 K 14/705; C07 K 16/28; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09; C12 N 15/12; G01 N 33/53
[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)
[KWD](#) | [Draw Desc](#) | [Image](#)

20. Document ID: JP 11501632 W, WO 9627292 A1, AU 9653044 A, BR 9607146 A, US 5733540 A, EP 871363 A1, AU 696449 B

L1: Entry 20 of 31

File: DWPI

Feb 9, 1999

DERWENT-ACC-NO: 1996-425139

DERWENT-WEEK: 199916

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Protecting animal against viral infection - using transformed bacteria to colonise mucosal surface, esp. useful against e.g. HIV, gonorrhoea, syphilis, Chlamydia and Epstein-Barr virus

INVENTOR: LEE, P P

PRIORITY-DATA: 1995US-0401070 (March 8, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 11501632 W	February 9, 1999		041	A61K035/74
WO 9627292 A1	September 12, 1996	E	037	A01N063/00
AU 9653044 A	September 23, 1996		000	A01N063/00
BR 9607146 A	November 25, 1997		000	A01N063/00
US 5733540 A	March 31, 1998		012	A01N063/00
EP 871363 A1	October 21, 1998	E	000	A01N063/00
AU 696449 B	September 10, 1998		000	A01N063/00

INT-CL (IPC) : A01 N 63/00; A61 K 9/00; A61 K 35/74; A61 K 38/46; C12 N 1/20; C12 N 1/21; C12 N 7/00; C12 N 7/04; C12 N 15/09; C12 P 21/02; C12 N 15/09; C12 R 1:91

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KWD](#) | [Draw Desc](#) | [Image](#)
[Generate Collection](#)
[Print](#)

Term	Documents
HYALURON\$	0
HYALURON.DWPI,EPAB,JPAB.	7
HYALURONAD.DWPI,EPAB,JPAB.	1
HYALURONAK.DWPI,EPAB,JPAB.	1
HYALURONAN.DWPI,EPAB,JPAB.	102
HYALURONANE.DWPI,EPAB,JPAB.	2
HYALURONANS.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIAT.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIATED.DWPI,EPAB,JPAB.	3
HYALURONAN-BASED.DWPI,EPAB,JPAB.	1
((HYALURON\$) SAME (HIV OR AIDS)).JPAB,EPAB,DWPI.	31

There are more results than shown above. Click here to view the entire set.

Display Format:

[Previous Page](#) [Next Page](#)

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 21 through 30 of 31 returned.

21. Document ID: JP 08217680 A

L1: Entry 21 of 31

File: DWPI

Aug 27, 1996

DERWENT-ACC-NO: 1996-439477

DERWENT-WEEK: 199644

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Lubricant for preventing aids infection - comprises substance having anti-HIV action esp. carrageenan

PRIORITY-DATA: 1995JP-0047795 (February 13, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 08217680 A	August 27, 1996		004	A61K031/725

INT-CL (IPC): A61 K 9/06; A61 K 31/725[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMIC](#) [Draw Desc](#) [Image](#)

22. Document ID: US 5527893 A

L1: Entry 22 of 31

File: DWPI

Jun 18, 1996

DERWENT-ACC-NO: 1996-299900

DERWENT-WEEK: 199630

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Water insoluble biocompatible compsn. - comprising reaction prod. of acyl urea deriv. of hyaluronic acid and carbodiimide, useful e.g., as surgical aid to prevent adhesion.

INVENTOR: BURNS, J W; MILLER, R ; WALTS, A E

PRIORITY-DATA: 1992US-0997298 (December 23, 1992), 1987US-0100104 (September 18, 1987), 1990US-0543163 (June 25, 1990), 1991US-0703254 (May 20, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5527893 A	June 18, 1996		012	C07H005/06

INT-CL (IPC): A61 K 31/70; C07 H 1/00; C07 H 5/06; C07 H 13/02[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMIC](#) [Draw Desc](#) [Image](#)

23. Document ID: JP 08151328 A

L1: Entry 23 of 31

File: DWPI

Jun 11, 1996

DERWENT-ACC-NO: 1996-329426

DERWENT-WEEK: 199633

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Lubricant for prevention of AIDS infection - comprises Acidic polysaccharide
e.g. carrageenan and e.g. propylene glycol

PRIORITY-DATA: 1994JP-0317610 (November 28, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 08151328 A	June 11, 1996		005	A61K031/725

INT-CL (IPC): A61 K 9/06; A61 K 31/725; A61 K 35/80; A61 K 47/36

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KIMC](#) | [Draw Desc](#) | [Image](#)

24. Document ID: DE 4340438 A1

L1: Entry 24 of 31

File: DWPI

Jun 1, 1995

DERWENT-ACC-NO: 1995-201459

DERWENT-WEEK: 199527

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of bio-flavonoid, esp. rutin for retrovirus inactivation - useful in the treatment of AIDS

INVENTOR: BACKHAUS, E

PRIORITY-DATA: 1993DE-4340438 (November 27, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 4340438 A1	June 1, 1995		002	A61K031/35

INT-CL (IPC): A61 K 31/35

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KIMC](#) | [Draw Desc](#) | [Image](#)

25. Document ID: WO 9104279 A, DE 69018440 E, EP 443043 A, EP 443043 B1, ES 2070335 T3, JP 04505774 W

L1: Entry 25 of 31

File: DWPI

Apr 4, 1991

DERWENT-ACC-NO: 1991-117480

DERWENT-WEEK: 199116

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Prodn. of hyaluronic acid - by shear treatment to give low molecular weight acid

INVENTOR: AKASAKA, H; YAMAGUCHI, T

PRIORITY-DATA: 1989JP-0236731 (September 12, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9104279 A	April 4, 1991		000	
DE 69018440 E	May 11, 1995		000	C08B037/08
EP 443043 A	August 28, 1991		000	
EP 443043 B1	April 5, 1995	E	009	C08B037/08
ES 2070335 T3	June 1, 1995		000	C08B037/08
JP 04505774 W	October 8, 1992		005	C08B037/08

INT-CL (IPC): A61 K 7/00; A61 K 7/48; A61 K 31/725; A61 K 47/36; C08 B 37/08

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

26. Document ID: WO 9010031 A, DE 69013833 E, EP 418339 A, EP 418339 B1, SE 8900586 A, US 5190759 A, US 5358973 A

L1: Entry 26 of 31

File: DWPI

Sep 7, 1990

DERWENT-ACC-NO: 1990-290320

DERWENT-WEEK: 199038

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Compsn. for preventing tissue adhesion after surgery - contg. dextran and hyaluronic acid

INVENTOR: BUCKLEY, P; LINDBLAD, G

PRIORITY-DATA: 1989SE-0000586 (February 21, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9010031 A	September 7, 1990		000	
DE 69013833 E	December 8, 1994		000	C08L005/00
EP 418339 A	March 27, 1991		000	
EP 418339 B1	November 2, 1994	E	010	C08L005/00
SE 8900586 A	August 22, 1990		000	
US 5190759 A	March 2, 1993		004	A61F002/02
US 5358973 A	October 25, 1994		005	A01N025/04

INT-CL (IPC): A01N 25/04; A01N 43/04; A61F 2/02; A61K 31/71; A61K 31/715; C07H 5/04; C07H 5/06; C08B 37/02; C08L 5/00

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

27. Document ID: JP 2836952 B2, WO 9009401 A, EP 408731 A, JP 03503905 W, US 5783691 A

L1: Entry 27 of 31

File: DWPI

Dec 14, 1998

DERWENT-ACC-NO: 1990-275104

DERWENT-WEEK: 199904

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: New crosslinked hyaluronic acid gels - having phosphate ester bridges

INVENTOR: LINDQVIST, B; MALSON, T ; MAELSON, T

PRIORITY-DATA: 1989SE-0000422 (February 8, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2836952 B2	December 14, 1998		005	C08B037/08
WO 9009401 A	August 23, 1990		017	
EP 408731 A	January 23, 1991		000	
JP 03503905 W	August 29, 1991		000	
US 5783691 A	July 21, 1998		000	C07H005/04

INT-CL (IPC): A61 K 9/00; A61 K 31/72; A61 K 31/725; A61 K 47/36; C07 H 5/04; C08 B 37/08

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

28. Document ID: GB 2218429 A, JP 2587680 B2, DE 3915557 A, JP 01287103 A, FR 2631344 A, GB 2218429 B, DE 3915557 C

L1: Entry 28 of 31

File: DWPI

Nov 15, 1989

DERWENT-ACC-NO: 1989-334834

DERWENT-WEEK: 199714

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Producing finely powdered hyaluronic acid or sodium hyaluronate - using slurry in an organic liq. and a wet type grinder for cosmetic use

INVENTOR: FUJII, M; HATAKEYAMA, M ; KIRAKI, J ; KUROKAWA, Y ; SHINTO, T

PRIORITY-DATA: 1988JP-0116638 (May 13, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2218429 A	November 15, 1989		000	
JP 2587680 B2	March 5, 1997		004	C08B037/08
DE 3915557 A	November 23, 1989		026	
JP 01287103 A	November 17, 1989		000	
FR 2631344 A	November 17, 1989		011	
GB 2218429 B	June 26, 1991		000	
DE 3915557 C	October 24, 1991		000	

INT-CL (IPC): A61K 7/48; B02C 15/06; B02C 17/00; B02C 17/04; B02C 19/20; B02C 47/04; C08B 37/08; C08J 3/12

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

29. Document ID: JP 01225491 A

L1: Entry 29 of 31

File: DWPI

Sep 8, 1989

DERWENT-ACC-NO: 1989-304914

DERWENT-WEEK: 198942

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Prepn. of hyaluronic acid - by culturing hyaluronic acid by culturing e.g. streptococcus equi ATCC 9527 and supplying hydroxyl contg. cpd.

PRIORITY-DATA: 1988JP-0051364 (March 4, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 01225491 A	September 8, 1989		005	

INT-CL (IPC): C12P 19/04; C12R 1/46

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWD	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	----------------------------	-----------------------

30. Document ID: EP 240098 A, AU 8771074 A, CA 1277239 C, JP 01151521 A, JP 63045223 A, JP 90007577 B, PH 25964 A, US 4840941 A, ZA 8702359 A

L1: Entry 30 of 31

File: DWPI

Oct 7, 1987

DERWENT-ACC-NO: 1987-279443

DERWENT-WEEK: 198740

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treatment of diseases caused by retro-viruses - using an oligo-or polysaccharide having S-oxo:acid gps. attached to the saccharic carbon via a linking gp.

INVENTOR: KUNO, S; TABATA, A ; UENO, R

PRIORITY-DATA: 1986JP-0093019 (April 21, 1986), 1988JP-0233363 (March 25, 1986), 1986JP-0078470 (April 4, 1986), 1986JP-0078471 (April 4, 1986)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 240098 A	October 7, 1987	E	033	
AU 8771074 A	October 8, 1987		000	
CA 1277239 C	December 4, 1990		000	
JP 01151521 A	June 14, 1989		000	
JP 63045223 A	February 26, 1988		000	
JP 90007577 B	February 19, 1990		000	
PH 25964 A	January 13, 1992		000	A61K003/70
US 4840941 A	June 20, 1989		022	
ZA 8702359 A	February 24, 1988		000	

INT-CL (IPC): A61K 3/70; A61K 31/70; C04B 37/02; C07H 11/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWD	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	----------------------------	-----------------------

[Generate Collection](#)[Print](#)

Term	Documents
HYALURON\$	0
HYALURON.DWPI,EPAB,JPAB.	7
HYALURONAD.DWPI,EPAB,JPAB.	1
HYALURONAK.DWPI,EPAB,JPAB.	1
HYALURONAN.DWPI,EPAB,JPAB.	102
HYALURONANE.DWPI,EPAB,JPAB.	2
HYALURONANS.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIAT.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIATED.DWPI,EPAB,JPAB.	3
HYALURONAN-BASED.DWPI,EPAB,JPAB.	1
((HYALURON\$) SAME (HIV OR AIDS)).JPAB,EPAB,DWPI.	31

[There are more results than shown above. Click here to view the entire set.](#)

Display Format: [CIT](#) [Change Format](#)

[Previous Page](#) [Next Page](#)

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 31 through 31 of 31 returned.

31. Document ID: FR 2400902 A

L1: Entry 31 of 31

File: DWPI

Apr 27, 1979

DERWENT-ACC-NO: 1979-41018B

DERWENT-WEEK: 197922

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition

PRIORITY-DATA: 1977FR-0025518 (August 22, 1977), 1976FR-0020218 (July 2, 1976)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
FR 2400902 A	April 27, 1979		000	

INT-CL (IPC): A61K 31/41; A61K 37/54

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)
[KWD](#) | [Drawn Desc](#) | [Image](#)
[Generate Collection](#)[Print](#)

Term	Documents
HYALURON\$	0
HYALURON.DWPI,EPAB,JPAB.	7
HYALURONAD.DWPI,EPAB,JPAB.	1
HYALURONAK.DWPI,EPAB,JPAB.	1
HYALURONAN.DWPI,EPAB,JPAB.	102
HYALURONANE.DWPI,EPAB,JPAB.	2
HYALURONANS.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIAT.DWPI,EPAB,JPAB.	1
HYALURONAN-ASSOCIATED.DWPI,EPAB,JPAB.	3
HYALURONAN-BASED.DWPI,EPAB,JPAB.	1
((HYALURON\$) SAME (HIV OR AIDS)).JPAB,EPAB,DWPI.	31

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:[CIT](#)[Change Format](#)[Previous Page](#)[Next Page](#)

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 3 of 3 returned.

1. Document ID: US 5108904 A

L2: Entry 1 of 3

File: EPAB

Apr 28, 1992

PUB-NO: US005108904A

DOCUMENT-IDENTIFIER: US 5108904 A

TITLE: CD44 as a marker for HIV infection

PUBN-DATE: April 28, 1992

INVENTOR-INFORMATION:

NAME	COUNTRY
LANDAY, ALAN	US

INT-CL (IPC): G01N 33/533

EUR-CL (EPC): G01N033/569

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)
[KMC](#) [Draw Desc](#) [Image](#)

2. Document ID: US 6326152 B1, WO 9854366 A1, AU 9878133 A, US 6071743 A, EP 1015630 A1

L2: Entry 2 of 3

File: DWPI

Dec 4, 2001

DERWENT-ACC-NO: 1999-070224

DERWENT-WEEK: 200203

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Composition for inhibiting human immunodeficiency virus - containing either fragments of cellular genes that express proteins essential for productive infection, or inhibitors of these cellular gene products

INVENTOR: DAYN, A; DUNN, S J ; HOLZMAYER, T A

PRIORITY-DATA: 1998US-0087609 (May 29, 1998), 1997US-0867314 (June 2, 1997), 2000US-0587674 (June 5, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6326152 B1	December 4, 2001		000	C12Q001/68
WO 9854366 A1	December 3, 1998	E	085	C12Q001/68
AU 9878133 A	December 30, 1998		000	
US 6071743 A	June 6, 2000		000	C12N015/85
EP 1015630 A1	July 5, 2000	E	000	C12Q001/68

INT-CL (IPC): A61 K 48/00; C07 H 21/04; C12 N 5/02; C12 N 9/88; C12 N 15/00; C12 N 15/11; C12 N 15/63; C12 N 15/85; C12 P 19/34; C12 Q 1/32; C12 Q 1/68; G01 N 33/53

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)
[KMC](#) [Draw Desc](#) [Image](#)

3. Document ID: US 5108904 A

L2: Entry 3 of 3

File: DWPI

Apr 28, 1992

DERWENT-ACC-NO: 1992-166520

DERWENT-WEEK: 199220

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Method for discriminating between asymptomatic HIV infection and AIDS - by measuring CD44 antigens expressed on CD44 and CD8 T cells and CD18 and/or CD54 antigen expressed on CD8 T cells

INVENTOR: LANDAY, A

PRIORITY-DATA: 1990US-0499144 (March 26, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5108904 A	April 28, 1992		007	

INT-CL (IPC): G01N 33/53

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	----------------------------	-----------------------

[Generate Collection](#)[Print](#)

Term	Documents
CD44\$	0
CD44.DWPI,EPAB,JPAB.	112
CD44V.DWPI,EPAB,JPAB.	2
CD44VT.DWPI,EPAB,JPAB.	1
CD44V5.DWPI,EPAB,JPAB.	1
CD44V6.DWPI,EPAB,JPAB.	6
CD44V-SPECIFIC.DWPI,EPAB,JPAB.	2
CD44-BOUND.DWPI,EPAB,JPAB.	1
CD44-EXPRESSING.DWPI,EPAB,JPAB.	2
CD44-GENE.DWPI,EPAB,JPAB.	1
((CD44\$) SAME (HIV OR AIDS)).JPAB,EPAB,DWPI.	3

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:	CIT	Change Format
---------------------------------	---------------------	-------------------------------

Previous Page	Next Page
-------------------------------	---------------------------